var title_f10_45_10960="Aponeurotic ptosis";
var content_f10_45_10960=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F80069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F80069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Patient with ptosis of the right upper lid secondary to levator dehiscence",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 211px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the absence of the right upper lid crease. The patient is raising the right eyebrow to try and compensate for the ptosis. The left lid shows pseudoretraction because of Hering's law of equal innervation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael S Lee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_45_10960=[""].join("\n");
var outline_f10_45_10960=null;
var title_f10_45_10961="Skin ulceration Churg Strauss";
var content_f10_45_10961=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cutaneous ulceration on the elbow of a patient with eosinophilic granulomatosis with polyangiitis (Churg-Strauss).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_45_10961=[""].join("\n");
var outline_f10_45_10961=null;
var title_f10_45_10962="Patient information: Vitamin D deficiency (The Basics)";
var content_f10_45_10962=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15788\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/6/11361\">",
"         Foods and drinks with vitamin D",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/12/36034\">",
"         Patient information: Calcium and vitamin D for bone health (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/58/35746\">",
"         Patient information: Osteoporosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/57/13202\">",
"         Patient information: Vitamin D for babies and children (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?1/29/1491\">",
"         Patient information: Bone density testing (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/60/23491\">",
"         Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/49/25366\">",
"         Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/62/15331\">",
"         Patient information: Vitamin D deficiency (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Vitamin D deficiency (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/vitamin-d-deficiency-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H13396257\">",
"      <span class=\"h1\">",
"       What is a vitamin D deficiency?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A vitamin D deficiency is when you do not have enough vitamin D in your body. This is a problem, because the body needs vitamin D to absorb calcium and for other important jobs.",
"     </p>",
"     <p>",
"      People who do not have enough vitamin D can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have weak or soft bones, which can break easily or change in shape",
"       </li>",
"       <li>",
"        Have weak muscles, which makes them more likely to fall",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13396264\">",
"      <span class=\"h1\">",
"       Is there a test for vitamin D deficiency?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse can do a blood test to see if you have enough vitamin D. But you might not need this test. Doctors measure vitamin D levels only in people who are at risk for a vitamin D deficiency. This includes people who:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Spend most or all of their time indoors (for example, because they are in a nursing home)",
"       </li>",
"       <li>",
"        Have medical problems (such as Celiac disease) that make it hard from them to absorb vitamin D",
"       </li>",
"       <li>",
"        Have a condition called &ldquo;osteoporosis,&rdquo; which makes bones weak",
"       </li>",
"       <li>",
"        Broke a bone too easily, such as by falling down",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13396271\">",
"      <span class=\"h1\">",
"       What foods and drinks have vitamin D?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Foods and drinks that have a lot of vitamin D include (",
"      <a class=\"graphic graphic_figure graphicRef78586 \" href=\"UTD.htm?11/6/11361\">",
"       figure 1",
"      </a>",
"      ):",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Milk, orange juice, or yogurt with vitamin D added",
"       </li>",
"       <li>",
"        Cooked salmon or mackerel",
"       </li>",
"       <li>",
"        Canned tuna fish",
"       </li>",
"       <li>",
"        Cereals with vitamin D added",
"       </li>",
"       <li>",
"        Cod liver oil",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People&rsquo;s bodies can also get vitamin D from the sun. The body uses sunlight that shines on the skin to make vitamin D.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13396278\">",
"      <span class=\"h1\">",
"       What are supplements?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Supplements are pills, capsules, or liquids that have nutrients in them. Supplements are another way people can get vitamin D.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13396285\">",
"      <span class=\"h1\">",
"       Do I need to take vitamin D supplements?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Experts recommend that most adults take supplements that have 800 international units of vitamin D a day. People who do not get enough vitamin D from their food or from the sun might need to take even more.",
"     </p>",
"     <p>",
"      If your doctor recommends that you take vitamin D supplements, ask him or her which type, how much, and when to take the supplements.",
"     </p>",
"     <p>",
"      The type and dose of supplement that is right for you will depend on your medical problems and the other medicines you take.",
"     </p>",
"     <p>",
"      It is important not to take too much vitamin D. Taking too much vitamin D can make you sick.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13396346\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/58/35746?source=see_link\">",
"       Patient information: Osteoporosis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=see_link\">",
"       Patient information: Calcium and vitamin D for bone health (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/57/13202?source=see_link\">",
"       Patient information: Vitamin D for babies and children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"       Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"       Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/29/1491?source=see_link\">",
"       Patient information: Bone density testing (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/62/15331?source=see_link\">",
"       Patient information: Vitamin D deficiency (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?10/45/10962?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15788 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-82D89F4E57-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_45_10962=[""].join("\n");
var outline_f10_45_10962=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13396257\">",
"      What is a vitamin D deficiency?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13396264\">",
"      Is there a test for vitamin D deficiency?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13396271\">",
"      What foods and drinks have vitamin D?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13396278\">",
"      What are supplements?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13396285\">",
"      Do I need to take vitamin D supplements?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13396346\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15788\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/6/11361\">",
"      Foods and drinks with vitamin D",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/29/1491?source=related_link\">",
"      Patient information: Bone density testing (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/58/35746?source=related_link\">",
"      Patient information: Osteoporosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=related_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/62/15331?source=related_link\">",
"      Patient information: Vitamin D deficiency (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/57/13202?source=related_link\">",
"      Patient information: Vitamin D for babies and children (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_45_10963="Treatment protocols for colorectal cancer";
var content_f10_45_10963=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment protocols for colorectal cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/45/10963/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/45/10963/contributors\">",
"     Tim Brenner, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/45/10963/contributors\">",
"     Shrina Duggal, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/45/10963/contributors\">",
"     Jim Natale, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/45/10963/contributors\">",
"     Scott M Wirth, PharmD, BCOP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/45/10963/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/45/10963/contributors\">",
"     John W Mucenski, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/45/10963/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/45/10963/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/45/10963/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H15188773\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following material represents a subset of chemotherapy regimens that are used for the treatment of patients with colorectal cancer, both in the adjuvant setting and for advanced disease.",
"    <strong>",
"     This is",
"    </strong>",
"    <strong>",
"     not an exhaustive list",
"    </strong>",
"    ; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with colorectal cancer. Additional regimens may be added over time, particularly as treatment for colorectal cancer evolves.",
"   </p>",
"   <p>",
"    This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with colorectal cancer. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21833?source=see_link\">",
"       \"Systemic chemotherapy for metastatic colorectal cancer: General principles\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44058?source=see_link\">",
"       \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41466?source=see_link\">",
"       \"Therapy for metastatic colorectal cancer in elderly patients and those with a poor performance status\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=see_link\">",
"       \"Management of potentially resectable colorectal cancer liver metastases\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link\">",
"       \"Adjuvant therapy for resected stage III (node-positive) colon cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30586?source=see_link\">",
"       \"Adjuvant chemotherapy for resected stage II colon cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4922?source=see_link\">",
"       \"Adjuvant therapy for resected rectal cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15188796\">",
"    <span class=\"h1\">",
"     REGIMENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15189144\">",
"    <span class=\"h2\">",
"     Short-term infusional fluorouracil and leucovorin (modified de Gramont schedule)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef65525 \" href=\"UTD.htm?36/17/37149\">",
"     table 1",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30672543\">",
"    <span class=\"h2\">",
"     Weekly bolus fluorouracil plus high-dose leucovorin (Roswell Park Memorial Institute [RPMI] regimen)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef86658 \" href=\"UTD.htm?43/34/44589\">",
"     table 2",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15189229\">",
"    <span class=\"h2\">",
"     Modified FOLFOX6 (fluorouracil plus leucovorin and oxaliplatin)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef50132 \" href=\"UTD.htm?16/53/17246\">",
"     table 3",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15189236\">",
"    <span class=\"h2\">",
"     Modified FOLFOX6 plus bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef62939 \" href=\"UTD.htm?30/6/30830\">",
"     table 4",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15189243\">",
"    <span class=\"h2\">",
"     Modified FOLFOX7",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef55829 \" href=\"UTD.htm?10/19/10558\">",
"     table 5",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15189250\">",
"    <span class=\"h2\">",
"     Modified FOLFOX7 plus bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef75802 \" href=\"UTD.htm?23/8/23694\">",
"     table 6",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H932900316\">",
"    <span class=\"h2\">",
"     Capecitabine plus oxaliplatin (XELOX, CAPOX)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef61781 \" href=\"UTD.htm?13/60/14286\">",
"     table 7",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H932900341\">",
"    <span class=\"h2\">",
"     XELOX/CAPOX plus bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef53192 \" href=\"UTD.htm?20/41/21150\">",
"     table 8",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H932900391\">",
"    <span class=\"h2\">",
"     FOLFIRI (fluorouracil plus leucovorin and irinotecan)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef76300 \" href=\"UTD.htm?19/2/19502\">",
"     table 9",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H932900416\">",
"    <span class=\"h2\">",
"     FOLFIRI plus bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef64505 \" href=\"UTD.htm?31/41/32414\">",
"     table 10",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H932900466\">",
"    <span class=\"h2\">",
"     FOLFOXIRI (fluorouracil plus leucovorin, oxaliplatin, and irinotecan)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef70559 \" href=\"UTD.htm?3/32/3599\">",
"     table 11",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H932900616\">",
"    <span class=\"h2\">",
"     Weekly single agent cetuximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef76312 \" href=\"UTD.htm?19/32/19981\">",
"     table 12",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8791457\">",
"    <span class=\"h2\">",
"     Single agent panitumumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef86309 \" href=\"UTD.htm?20/42/21165\">",
"     table 13",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15188984\">",
"    <span class=\"h2\">",
"     Cetuximab plus irinotecan",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef62096 \" href=\"UTD.htm?14/1/14366\">",
"     table 14",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8791396\">",
"    <span class=\"h2\">",
"     FOLFIRI plus cetuximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef62726 \" href=\"UTD.htm?1/39/1663\">",
"     table 15",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8791403\">",
"    <span class=\"h2\">",
"     FOLFIRI plus panitumumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef86311 \" href=\"UTD.htm?34/40/35470\">",
"     table 16",
"    </a>",
"    )",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85679 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-87E6A227E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_45_10963=[""].join("\n");
var outline_f10_45_10963=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15188773\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15188796\">",
"      REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15189144\">",
"      Short-term infusional fluorouracil and leucovorin (modified de Gramont schedule)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30672543\">",
"      Weekly bolus fluorouracil plus high-dose leucovorin (Roswell Park Memorial Institute [RPMI] regimen)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15189229\">",
"      Modified FOLFOX6 (fluorouracil plus leucovorin and oxaliplatin)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15189236\">",
"      Modified FOLFOX6 plus bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15189243\">",
"      Modified FOLFOX7",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15189250\">",
"      Modified FOLFOX7 plus bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H932900316\">",
"      Capecitabine plus oxaliplatin (XELOX, CAPOX)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H932900341\">",
"      XELOX/CAPOX plus bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H932900391\">",
"      FOLFIRI (fluorouracil plus leucovorin and irinotecan)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H932900416\">",
"      FOLFIRI plus bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H932900466\">",
"      FOLFOXIRI (fluorouracil plus leucovorin, oxaliplatin, and irinotecan)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H932900616\">",
"      Weekly single agent cetuximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8791457\">",
"      Single agent panitumumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15188984\">",
"      Cetuximab plus irinotecan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8791396\">",
"      FOLFIRI plus cetuximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8791403\">",
"      FOLFIRI plus panitumumab",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/85679\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/85679|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/17/37149\" title=\"table 1\">",
"      Modified de Gramont schedule for gastrointestinal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/34/44589\" title=\"table 2\">",
"      Weekly fluorouracil plus leucovorin for colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/53/17246\" title=\"table 3\">",
"      Modified FOLFOX6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/6/30830\" title=\"table 4\">",
"      Modified FOLFOX6 plus bevacizumab chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/19/10558\" title=\"table 5\">",
"      Modified FOLFOX7 regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/8/23694\" title=\"table 6\">",
"      Modified FOLFOX7 plus bevacizumab chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/60/14286\" title=\"table 7\">",
"      XELOX regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/41/21150\" title=\"table 8\">",
"      XELOX plus bevacizumab regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/2/19502\" title=\"table 9\">",
"      FOLFIRI regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/41/32414\" title=\"table 10\">",
"      FOLFIRI plus bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/32/3599\" title=\"table 11\">",
"      FOLFOXIRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/32/19981\" title=\"table 12\">",
"      Cetuximab monotherapy colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/42/21165\" title=\"table 13\">",
"      Panitumumab monotherapy CRC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/1/14366\" title=\"table 14\">",
"      Cetuximab plus irinotecan for colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/39/1663\" title=\"table 15\">",
"      FOLFIRI plus cetuximab for colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/40/35470\" title=\"table 16\">",
"      FOLFIRI plus panitumumab for colorectal cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30586?source=related_link\">",
"      Adjuvant chemotherapy for resected stage II colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4922?source=related_link\">",
"      Adjuvant therapy for resected rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=related_link\">",
"      Adjuvant therapy for resected stage III (node-positive) colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=related_link\">",
"      Management of potentially resectable colorectal cancer liver metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21833?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44058?source=related_link\">",
"      Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41466?source=related_link\">",
"      Therapy for metastatic colorectal cancer in elderly patients and those with a poor performance status",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_45_10964="Silver sulfadiazine: Drug information";
var content_f10_45_10964=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Silver sulfadiazine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/48/42756?source=see_link\">",
"    see \"Silver sulfadiazine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/36/9795?source=see_link\">",
"    see \"Silver sulfadiazine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Silvadene&reg;;",
"     </li>",
"     <li>",
"      SSD&trade;;",
"     </li>",
"     <li>",
"      Thermazene&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F221121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Flamazine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F221136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F221123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Antiseptic, burns:",
"     </b>",
"     Topical: Apply once or twice daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F221132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/36/9795?source=see_link\">",
"      see \"Silver sulfadiazine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F221124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F221103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 1% (25 g, 50 g, 85 g, 400 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Silvadene&reg;: 1% (20 g, 50 g, 85 g, 400 g, 1000 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SSD&trade;: 1% (25 g, 50 g, 85 g, 400 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thermazene&reg;: 1% (20 g, 25 g, 50 g, 85 g, 400 g, 1000 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F221089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F803229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apply with a sterile-gloved hand. Apply to a thickness",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      16",
"     </sub>",
"     &rdquo;. Burned area should be covered with cream at all times.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F221104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of infection in second and third degree burns",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F221134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Discoloration of skin, erythema multiforme, itching, photosensitivity, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, hemolytic anemia, leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Interstitial nephritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions may be related to sulfa component",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F221108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to silver sulfadiazine or any component of the formulation; premature infants or neonates &lt;2 months of age (sulfonamides may displace bilirubin and cause kernicterus); pregnancy (approaching or at term)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F221093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Systemic absorption may be significant and adverse reactions may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       DIsease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Use with caution in patients with G6PD deficiency; hemolysis may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; sulfadiazine may accumulate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; sulfadiazine may accumulate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Analgesics: Use of an analgesic might be needed before application.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F221097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F221099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9611621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Because of the theoretical increased risk for hyperbilirubinemia and kernicterus, sulfadiazine is contraindicated for use near term, on premature infants, or on newborn infants during the first 2 months of life (refer to Sulfadiazine monograph).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F221127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9611623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if sulfadiazine is found in breast milk following topical application; however, sulfonamide serum concentrations may reach therapeutic levels following application to extensive areas. Oral sulfadiazine is contraindicated in nursing mothers since sulfonamides cross into the milk and may cause kernicterus in the newborn (refer to Sulfadiazine monograph).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F221111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Silvadene External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (85 g): $29.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Silver Sulfadiazine External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (50 g): $14.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (SSD External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (50 g): $14.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Thermazene External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (50 g): $8.64",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F221101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum electrolytes, urinalysis, renal function tests, CBC in patients with extensive burns on long-term treatment",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F221112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aldo-Silvederma (HK);",
"     </li>",
"     <li>",
"      Argentafil (CR, NI, PA, SV);",
"     </li>",
"     <li>",
"      Argentamicina (PE);",
"     </li>",
"     <li>",
"      Argenzil (UY);",
"     </li>",
"     <li>",
"      Burnazin (ID);",
"     </li>",
"     <li>",
"      Burnsil (PH);",
"     </li>",
"     <li>",
"      Dermazin (HK, PL, RU, TH);",
"     </li>",
"     <li>",
"      Dermazine (BR);",
"     </li>",
"     <li>",
"      Flamazine (AE, AU, BH, CY, DK, EG, FI, GB, IQ, IR, JO, KW, LB, LY, NO, NZ, OM, PK, QA, SA, SY, TH, TW, YE, ZA);",
"     </li>",
"     <li>",
"      Flammazine (AT, BE, BG, CH, DE, ES, FR, GR, NL, PH, PT);",
"     </li>",
"     <li>",
"      Flugen (TW);",
"     </li>",
"     <li>",
"      Platsul-A (AR, CN);",
"     </li>",
"     <li>",
"      Silmazin (KP);",
"     </li>",
"     <li>",
"      Silvadene (MX, TR, TW);",
"     </li>",
"     <li>",
"      Silvadin (EC);",
"     </li>",
"     <li>",
"      Silvazine (AU);",
"     </li>",
"     <li>",
"      Silvederma (ES, VE);",
"     </li>",
"     <li>",
"      Silverdiazina (PE);",
"     </li>",
"     <li>",
"      Silverol (IL);",
"     </li>",
"     <li>",
"      Silvex (HK);",
"     </li>",
"     <li>",
"      Silvirin (IN);",
"     </li>",
"     <li>",
"      Sofargen (IT);",
"     </li>",
"     <li>",
"      Sterizol (PH);",
"     </li>",
"     <li>",
"      Sulfadiacina de Plata (PY);",
"     </li>",
"     <li>",
"      Sulfadin (PH);",
"     </li>",
"     <li>",
"      Sulfaplata (CO, DO, GT, HN, PA, SV);",
"     </li>",
"     <li>",
"      Sulfargin (EE);",
"     </li>",
"     <li>",
"      Synvodex (PH);",
"     </li>",
"     <li>",
"      Uburn (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F221092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acts upon the bacterial cell wall and cell membrane. Bactericidal for many gram-negative and gram-positive bacteria and is effective against yeast. Active against",
"     <i>",
"      Pseudomonas aeruginosa",
"     </i>",
"     ,",
"     <i>",
"      Pseudomonas maltophilia",
"     </i>",
"     ,",
"     <i>",
"      Enterobacter",
"     </i>",
"     species,",
"     <i>",
"      Klebsiella",
"     </i>",
"     species,",
"     <i>",
"      Serratia",
"     </i>",
"     species,",
"     <i>",
"      Escherichia coli",
"     </i>",
"     ,",
"     <i>",
"      Proteus mirabilis",
"     </i>",
"     ,",
"     <i>",
"      Morganella morganii",
"     </i>",
"     ,",
"     <i>",
"      Providencia rettgeri",
"     </i>",
"     ,",
"     <i>",
"      Proteus vulgaris",
"     </i>",
"     ,",
"     <i>",
"      Providencia",
"     </i>",
"     species,",
"     <i>",
"      Citrobacter",
"     </i>",
"     species,",
"     <i>",
"      Acinetobacter calcoaceticus",
"     </i>",
"     ,",
"     <i>",
"      Staphylococcus aureus",
"     </i>",
"     ,",
"     <i>",
"      Staphylococcus epidermidis",
"     </i>",
"     ,",
"     <i>",
"      Enterococcus",
"     </i>",
"     species,",
"     <i>",
"      Candida albicans",
"     </i>",
"     ,",
"     <i>",
"      Corynebacterium diphtheriae",
"     </i>",
"     , and",
"     <i>",
"      Clostridium perfringens",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F221107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Significant percutaneous absorption of silver sulfadiazine can occur especially when applied to extensive burns",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 10 hours; prolonged with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 3-11 days of continuous therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~50% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Kulick MI, Wong R, Okarma TB, et al, &ldquo;Prospective Study of Side Effects Associated With the Use of Silver Sulfadiazine in Severely Burned Patients,&rdquo;",
"      <i>",
"       Ann Plast Surg",
"      </i>",
"      , 1985, 14(5):407-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10964/abstract-text/4083697/pubmed\" id=\"4083697\" target=\"_blank\">",
"        4083697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lockhart SP, Rushworth A, Azmy AA, et al, &ldquo;Topical Silver Sulfadiazine: Side Effects and Urinary Excretion,&rdquo;",
"      <i>",
"       Burns Incl Therm Inj",
"      </i>",
"      , 1983, 10(1):9-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10964/abstract-text/6640389/pubmed\" id=\"6640389\" target=\"_blank\">",
"        6640389",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9890 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-17F8E0A872-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_45_10964=[""].join("\n");
var outline_f10_45_10964=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221120\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221121\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221136\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221123\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221132\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221124\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221103\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221089\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F803229\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221104\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221134\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221108\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221093\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300042\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221097\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221099\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611621\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221127\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611623\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221111\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221101\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221112\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221092\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221107\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9890\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9890|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/48/42756?source=related_link\">",
"      Silver sulfadiazine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/36/9795?source=related_link\">",
"      Silver sulfadiazine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_45_10965="Estramustine: Patient drug information";
var content_f10_45_10965=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Estramustine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/4/35909?source=see_link\">",
"     see \"Estramustine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F167308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Emcyt&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F167309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Emcyt&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692030",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat prostate cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to estramustine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703723",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have blood clots.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a stroke, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698612",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Breast soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698200",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Leg cramps.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698126",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the heart may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698227",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the lungs may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694759",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take dairy products or calcium within 2 hours of this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11367 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6D34BE7A96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_45_10965=[""].join("\n");
var outline_f10_45_10965=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167308\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167309\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021536\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021538\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021537\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021542\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021543\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021545\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021540\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021541\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021546\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021547\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/4/35909?source=related_link\">",
"      Estramustine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_45_10966="Care during pregnancy for women with type 1 or 2 diabetes mellitus";
var content_f10_45_10966=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?10/45/10966/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/45/10966/contributors\" id=\"au4555\">",
"       Vanessa A Barss, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/45/10966/contributors\" id=\"au4987\">",
"       John T Repke, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?10/45/10966/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/45/10966/contributors\" id=\"se4723\">",
"       Charles J Lockwood, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/45/10966/contributors\" id=\"se6384\">",
"       David M Nathan, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?10/45/10966/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/45/10966/contributors\" id=\"de1470\">",
"       Jean E Mulder, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?10/45/10966?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Before insulin became available in 1922, women with diabetes mellitus were at very high risk of complications of pregnancy. Today, most women with diabetes can have a safe pregnancy and delivery, similar to that of nondiabetic women. This improvement is largely due to good blood glucose (sugar) control, which requires adherence to diet, frequent daily blood glucose monitoring, and frequent insulin adjustment.",
"    </p>",
"    <p>",
"     This topic review discusses care of women with type 1 or 2 diabetes during pregnancy, as well as fetal and newborn issues. It does not address gestational diabetes, which develops during pregnancy. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/13/32979?source=see_link\">",
"      \"Patient information: Gestational diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      IMPORTANCE OF BLOOD GLUCOSE CONTROL",
"     </span>",
"    </p>",
"    <p>",
"     Glucose in the mother's blood crosses the placenta to provide energy for the baby; thus, high blood glucose levels in the mother lead to high blood glucose levels in the developing baby as well.",
"    </p>",
"    <p>",
"     High blood glucose levels can cause several problems:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Early in pregnancy, high glucose levels increase the risk of miscarriage and birth defects. These risks are highest when hemoglobin A1C is &gt;8 percent or the average blood glucose is &gt;180",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (10",
"       <span class=\"nowrap\">",
"        mmol/L).",
"       </span>",
"      </li>",
"      <li>",
"       In the last half of pregnancy and near delivery, high blood glucose levels can cause the baby's size and weight to be larger than normal and increase the risk of complications during and after delivery (see",
"       <a class=\"local\" href=\"#H19\">",
"        'Newborn issues'",
"       </a>",
"       below). In particular, women with large babies are more likely to have difficulty having a vaginal birth and have a higher chance of needing a cesarean delivery.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     These complications occur less frequently when blood glucose levels are carefully controlled.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7453702\">",
"     <span class=\"h2\">",
"      General measures to control blood glucose",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Women with type 2 diabetes who have been treated with diet or oral medications generally require insulin for blood glucose control during pregnancy. Oral diabetes medications (eg, glyburide, metformin) have been used to manage type 2 diabetes during pregnancy in some cases. These medications can control blood glucose levels, but multiple large studies of their safety and efficacy have not been performed. For this reason, the American College of Obstetricians and Gynecologists and American Diabetes Association do not recommend using these medications during pregnancy. Women who are taking these medications when they become pregnant should speak with their healthcare provider, and may be switched to insulin therapy.",
"      </li>",
"      <li>",
"       Most women with type 1 diabetes will require two to four insulin injections per day. Women who use an insulin pump may continue to do so during pregnancy. Women with diabetes need more insulin during pregnancy, especially during the last one-third of pregnancy (approximately 26 to 40 weeks of pregnancy) because the body becomes resistant to insulin as the pregnancy progresses. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=see_link\">",
"        \"Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Frequent contact with healthcare providers is important for managing blood glucose levels and monitoring the health of the woman and her baby. The healthcare provider may want to review blood glucose levels and insulin doses one or more times per week; this can usually be done via telephone, e-mail, or fax.",
"      </li>",
"      <li>",
"       A nutritionist can help to plan a diet for pregnant diabetic women that provides the optimal number of calories, carbohydrate, and",
"       <span class=\"nowrap\">",
"        snacks/meals",
"       </span>",
"       throughout the day. The optimal number of calories depends upon the woman's prepregnancy weight and activity level.",
"      </li>",
"      <li>",
"       Exercise is an excellent way to control weight and blood glucose levels. Most women who exercised before pregnancy can continue to do so during pregnancy at the same or a slightly reduced pace. Moderate intensity exercise, such as brisk walking, is recommended. Women who did not exercise previously may begin to exercise during pregnancy after consulting with their healthcare provider. Exercise intensity, type, and duration may need to be modified as the pregnancy progresses or if complications develop. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?7/30/7657?source=see_link\">",
"        \"Recommendations for exercise during pregnancy and the postpartum period\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7453710\">",
"     <span class=\"h2\">",
"      Target blood glucose levels",
"     </span>",
"     &nbsp;&mdash;&nbsp;Frequent blood glucose monitoring is recommended during pregnancy, including testing before and after each meal. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"      \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .) Target blood glucose levels during pregnancy are slightly lower than those of non-pregnant people.",
"    </p>",
"    <p>",
"     The American College of Obstetricians and Gynecologists recommends the following goals when self-monitoring blood glucose levels during pregnancy:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Fasting glucose concentrations &le;95",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (5.3",
"       <span class=\"nowrap\">",
"        mmol/L)",
"       </span>",
"      </li>",
"      <li>",
"       Preprandial glucose concentrations no higher than 100",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (5.6",
"       <span class=\"nowrap\">",
"        mmol/L)",
"       </span>",
"      </li>",
"      <li>",
"       One-hour postprandial glucose concentrations no higher than 140",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (7.8",
"       <span class=\"nowrap\">",
"        mmol/L)",
"       </span>",
"      </li>",
"      <li>",
"       Two-hour postprandial glucose concentrations no higher than 120",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (6.7",
"       <span class=\"nowrap\">",
"        mmol/L)",
"       </span>",
"      </li>",
"      <li>",
"       Mean capillary glucose 100",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (5.6",
"       <span class=\"nowrap\">",
"        mmol/L)",
"       </span>",
"      </li>",
"      <li>",
"       During the night, glucose levels should not decrease to less than 60",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (3.3",
"       <span class=\"nowrap\">",
"        mmol/L)",
"       </span>",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The American Diabetes Association recommends the following glucose goals:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Preprandial, bedtime, and overnight glucose concentrations 60 to 99",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (3.3 to 5.5",
"       <span class=\"nowrap\">",
"        mmol/L)",
"       </span>",
"      </li>",
"      <li>",
"       Peak postprandial glucose concentrations 100 to 129",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (5.6 to 7.2",
"       <span class=\"nowrap\">",
"        mmol/L)",
"       </span>",
"       one to two hours after the beginning of the meal",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Hemoglobin A1C is a blood test that represents the average blood glucose level over the previous two to three months. This test is usually done once per month during pregnancy. The goal is for the A1C to be at or near normal (6 percent or an average blood glucose of 120",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     [6.7",
"     <span class=\"nowrap\">",
"      mmol/L])",
"     </span>",
"     (",
"     <a class=\"graphic graphic_table graphicRef76310 \" href=\"UTD.htm?6/10/6316\">",
"      table 1",
"     </a>",
"     ). However, attempting to be at or below 6 percent can cause frequent episodes of low blood glucose, so target A1C goals should be determined individually. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/63/4083?source=see_link\">",
"      \"Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      CARE DURING PREGNANCY",
"     </span>",
"    </p>",
"    <p>",
"     Ideally, a woman with diabetes who is planning pregnancy should consult her healthcare provider well before she becomes pregnant. This provides an opportunity to make sure blood glucose levels are in optimal control, adjust medications if needed, evaluate and treat any medical complications related to diabetes (such as diabetes-related eye disease), and start folic acid supplementation (at least 400 mcg per day is recommended, starting at least one month before conception). It is also an opportunity to discuss how pregnancy may affect diabetes and vice versa.",
"    </p>",
"    <p>",
"     Care during pregnancy is a team effort involving an obstetrician and an endocrinologist or internist who oversees insulin management and medical care. Some family practitioners perform all of these functions.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Eye examination",
"     </span>",
"     &nbsp;&mdash;&nbsp;Retinopathy refers to abnormal, leaky blood vessels in the light sensitive tissue lining the back of the eye (the retina). Retinopathy can lead to vision problems, and even blindness in severe cases. Pregnancy can worsen diabetic retinopathy. The risk of worsening retinopathy during pregnancy is increased in those with the highest initial A1C values and in women whose A1C falls rapidly during pregnancy.",
"    </p>",
"    <p>",
"     The impact of pregnancy on diabetic retinopathy is mild and temporary for most women; the retina usually returns to its prepregnancy condition within several months after delivery. Nevertheless, all women with type 1 or 2 diabetes should have an eye examination by an ophthalmologist or optometrist before pregnancy and during the first trimester (three months). In most cases, a follow-up examination is recommended every three months until delivery, depending upon the results of the initial examination.",
"    </p>",
"    <p>",
"     Women with severe retinopathy are more likely to experience progression and complications. Eye examinations before and during pregnancy, along with close monitoring and treatment (as needed) of retinopathy can minimize the risk of vision loss. Some experts have recommended cesarean delivery for women with retinopathy, but this is controversial; most women can attempt a vaginal delivery.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Blood pressure monitoring",
"     </span>",
"     &nbsp;&mdash;&nbsp;Blood pressure may become elevated during pregnancy and should be measured at every appointment. High blood pressure often improves during the first half of pregnancy, but returns to baseline or worsens in the second half.",
"    </p>",
"    <p>",
"     Medications to treat high blood pressure during pregnancy may include methyldopa, calcium channel blocking agents, hydralazine, or beta blockers. Beta blockers can mask some symptoms of low blood glucose and should be used with caution.",
"    </p>",
"    <p>",
"     Angiotensin converting enzyme (ACE) inhibitors (captopril, lisinopril, enalapril) and angiotensin II receptor blockers (ARBs, losartan, valsartan) are not safe for the fetus, and should be discontinued in any woman planning pregnancy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      High blood pressure complications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Gestational hypertension (high blood pressure during pregnancy) and preeclampsia (high blood pressure and protein in the urine during pregnancy) are more common in women with diabetes. Fortunately, most cases are mild. In severe cases, seizure, stroke, heart failure, kidney damage, and rarely, maternal death can occur. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/58/40867?source=see_link\">",
"      \"Patient information: Preeclampsia (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Kidney function monitoring",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pregnancy does not cause diabetes-related kidney disease (called diabetic nephropathy), but it can worsen existing disease. Kidney function is monitored during pregnancy by urine dipstick testing for protein, which is usually performed at every prenatal visit. Other urine or blood tests may be ordered depending upon the individual's situation.",
"    </p>",
"    <p>",
"     Diabetic nephropathy may increase the risk of developing other pregnancy complications, such as preeclampsia, preterm delivery, and babies who are small for their age (intrauterine growth restriction). Women with these complications have a higher frequency of hospitalization during pregnancy and cesarean delivery. Women with retinopathy and kidney disease are at increased risk of having a small infant because blood flow to the placenta may be reduced.",
"    </p>",
"    <p>",
"     If a woman develops worsening nephropathy during pregnancy, it is usually temporary and reverts to the prepregnancy condition within several months of delivery. Nephropathy probably worsens because blood flow through the kidney increases by 50 percent during pregnancy, which increases the kidneys' workload. In addition, some women develop high blood pressure or new pregnancy-induced high blood pressure, which further stresses the kidney.",
"    </p>",
"    <p>",
"     Permanent kidney damage, including kidney failure, can occur in women who already have significant nephropathy before becoming pregnant. These women may require dialysis or kidney transplant sooner than a woman with severe chronic kidney disease who never becomes pregnant. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=see_link\">",
"      \"Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=see_link\">",
"      \"Patient information: Hemodialysis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Ultrasound",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ultrasound may be recommended for several reasons during pregnancy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      To determine the due date",
"     </span>",
"     &nbsp;&mdash;&nbsp;An ultrasound examination of the baby is recommended during the first trimester of pregnancy (before 13 weeks) if there is any uncertainty about the date of the last menstrual period. It is important that the due date is accurate because decisions about when to begin fetal testing and when to deliver the baby are based upon this date.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      To screen for birth defects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ultrasound examination is recommended at 18 to 20 weeks gestation to screen for birth defects. The examination should pay particular attention to the spine and heart because infants of diabetic mothers may be at increased risk for neural tube defects and heart defects.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      To monitor amniotic fluid levels",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ultrasound is also used to monitor the amount of amniotic fluid around the fetus; polyhydramnios is an abnormal increase in the amount of amniotic fluid. Polyhydramnios is more common in women with diabetes than in women without diabetes. Polyhydramnios related to diabetes is usually mild and does not cause problems. If the fluid levels become severely elevated, maternal discomfort, uterine contractions, premature rupture of the membranes (\"breaking the water\"), and preterm delivery can occur. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/52/35650?source=see_link\">",
"      \"Patient information: Preterm labor (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      To monitor the baby's growth",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ultrasound is also used to monitor the baby's growth and development throughout the pregnancy, although ultrasound estimates of the baby's weight can be off by as much as 15 percent. Macrosomia is a condition in which an infant weighs more than nine pounds (4000 grams) at term (&ge;37 weeks of pregnancy), and is more common in women with diabetes. High fetal insulin levels, which can develop in response to elevated maternal blood glucose levels, are one potential cause of macrosomia since insulin stimulates fetal growth.",
"    </p>",
"    <p>",
"     Macrosomia occurs in 15 to 45 percent of diabetic pregnancies. Cesarean delivery may be needed if labor does not progress normally because of the large size of the baby. In addition, macrosomic infants are at higher risk of being injured during delivery and may be delivered by cesarean delivery before labor if there is a concern that the infant's shoulders may be difficult to deliver through a woman's pelvis (called shoulder dystocia). Shoulder dystocia occurs in one out of four macrosomic births in women with diabetes.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Screening for birth defects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Birth defects are more common in infants of women with high blood glucose levels before and during the early weeks of pregnancy; most birth defects develop by the 10",
"     <sup>",
"      th",
"     </sup>",
"     week of pregnancy. There is no particular birth defect caused by maternal diabetes; neural tube defects and heart defects are the most common birth defects. However, studies have shown that very good blood glucose control before becoming pregnant reduces the risk of birth defects to a level that is similar to that of women who do not have diabetes. In addition, to reduce the risk of neural tube defects, women planning pregnancy should begin taking folic acid supplements in a multivitamin or prenatal vitamin one to two months prior to attempting to conceive and continue supplementation at least through the first trimester.",
"    </p>",
"    <p>",
"     Women with diabetes do not have a higher risk of having a baby with a chromosomal abnormality, such as Down syndrome, than women without diabetes. The risk of having a baby with Down syndrome primarily depends on the mother&rsquo;s age and whether there is a family history of Down syndrome. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/50/2851?source=see_link\">",
"      \"Patient information: Should I have a screening test for Down syndrome during pregnancy? (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Fetal testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Close monitoring of the fetus is recommended during the third trimester, usually starting at 32 weeks of pregnancy. This usually includes weekly to twice-weekly nonstress testing. This is done by monitoring the baby's heart rate with a small device that is placed on the mother's abdomen. The device uses sound waves (ultrasound) to measure the baby's heart rate over time, usually for 20 to 30 minutes.",
"    </p>",
"    <p>",
"     Normally, the baby's baseline heart rate should be between 110 and 160 beats per minute and should increase above its baseline by at least 15 beats per minute for 15 seconds when the baby moves.",
"    </p>",
"    <p>",
"     The test is considered reassuring (called \"reactive\") if two or more fetal heart rate increases are seen within a 20 minute period. Further testing may be needed if these increases are not seen after monitoring for 40 minutes.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      PLANNING FOR DELIVERY",
"     </span>",
"    </p>",
"    <p>",
"     A woman and her obstetrician may decide to schedule the date of her delivery (either an induction of labor or cesarean delivery), especially if there are risk factors, such as increased blood glucose levels, nephropathy, worsening retinopathy, high blood pressure or preeclampsia, or if the baby is smaller or larger than normal. If delivery before the due date is planned, an amniocentesis may be recommended to determine if the baby&rsquo;s lungs are ready for breathing. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/28/14785?source=see_link\">",
"      \"Patient information: Amniocentesis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If the fetus appears to be very large (based upon ultrasound measurements), a woman and her obstetrician may consider cesarean delivery to avoid possible trauma from shoulder dystocia. The American College of Obstetricians and Gynecologists suggests that a woman and her physician consider a planned cesarean delivery if the baby&rsquo;s estimated weight (by ultrasound measurement) is greater than 4500 grams (9 lbs, 14 oz). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=see_link\">",
"      \"Patient information: C-section (cesarean delivery) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Waiting for labor to start on its own is reasonable if blood glucose levels are well-controlled and the mother and baby are doing well. However, extending pregnancy beyond 40 to 41 weeks of gestation is generally not recommended; some practitioners routinely induce labor between 39 and 40 weeks in all women with type 1 or 2 diabetes.",
"    </p>",
"    <p>",
"     The risk of stillbirth for pregnant women with well-controlled diabetes is very low, and is about the same as in women without diabetes (less than 1 percent). The mortality (death) rate in infants of diabetic women is slightly higher than in nondiabetics (2 versus 1 percent). This is mostly due to a higher rate of serious birth defects in infants of diabetic mothers.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      INFANT CARE",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Newborn issues",
"     </span>",
"     &nbsp;&mdash;&nbsp;The infant of the diabetic mother is at risk for several problems in the newborn period, such as low blood glucose levels, jaundice, breathing problems, excessive red blood cells (polycythemia), low calcium level, and heart problems. These problems are more common when the mother's blood glucose levels have been high throughout the pregnancy. Most of these problems resolve within a few hours or days after delivery. Infants of diabetic mothers are often evaluated in a special care nursery to monitor for these potential problems.",
"    </p>",
"    <p>",
"     Infants of mothers with diabetes are at higher risk of having difficulties with breathing, especially if the infant is born earlier than 39 weeks. This is because the lungs appear to develop more slowly in infants of women with diabetes. The risk of breathing problems is highest when maternal blood glucose levels have been high near the time of delivery.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Will my child develop diabetes?",
"     </span>",
"     &nbsp;&mdash;&nbsp;The children of parents with diabetes are at increased risk of developing the same type of diabetes. According to the American Diabetes Association:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Children of a father with type 1 diabetes have a 1 in 17 risk of developing type 1 diabetes. Children of a mother with type 1 diabetes have a 1 in 25 risk if, at the time of pregnancy, the mother is less than 25 years of age. The risk is 1 in 100 risk if the mother is 25 years of age or older. These risks are doubled if the affected parent developed diabetes before age 11. If both parents have type 1 diabetes, the child's risk is 1 in 4 to 10 (10 to 25 percent risk).",
"      </li>",
"      <li>",
"       The risk of diabetes in children of a parent with type 2 diabetes is 1 in 7 if the parent was diagnosed before age 50 and 1 in 13 if the parent was diagnosed after age 50. The child's risk may be greater when the parent with type 2 diabetes is the mother. If both parents have type 2 diabetes, the risk to the child is about 1 in 2. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=see_link\">",
"        \"Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"        \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      AFTER DELIVERY CARE",
"     </span>",
"    </p>",
"    <p>",
"     Postpartum (after delivery) care of a woman with diabetes is similar to that of women without diabetes. However, it is important to pay close attention to blood glucose levels because insulin requirements change significantly in the first few days after delivery; some women require little or no insulin. Insulin requirements usually return to near-prepregnancy levels within 48 hours.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Breastfeeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;In all women (with and without diabetes), breastfeeding is strongly encouraged because it benefits both the infant and the mother. Insulin requirements may be lower while breastfeeding, and frequent blood glucose monitoring is important to prevent severe hypoglycemia. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"      \"Patient information: Deciding to breastfeed (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/19/1333?source=see_link\">",
"      \"Patient information: Breastfeeding guide (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498538555\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9142806\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/62/31714?source=see_link\">",
"      Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37907?source=see_link\">",
"      Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/47/15091?source=see_link\">",
"      Patient information: Preparing for pregnancy when you have diabetes (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9142843\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/13/32979?source=see_link\">",
"      Patient information: Gestational diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=see_link\">",
"      Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/63/4083?source=see_link\">",
"      Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/58/40867?source=see_link\">",
"      Patient information: Preeclampsia (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=see_link\">",
"      Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=see_link\">",
"      Patient information: Hemodialysis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/52/35650?source=see_link\">",
"      Patient information: Preterm labor (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/50/2851?source=see_link\">",
"      Patient information: Should I have a screening test for Down syndrome during pregnancy? (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/28/14785?source=see_link\">",
"      Patient information: Amniocentesis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=see_link\">",
"      Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=see_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"      Patient information: Deciding to breastfeed (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/19/1333?source=see_link\">",
"      Patient information: Breastfeeding guide (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/19/41272?source=see_link\">",
"      Benefits and complications associated with kidney-pancreas transplantation in diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link\">",
"      General principles of insulin therapy in diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20794?source=see_link\">",
"      Medical management of type 1 and type 2 diabetes mellitus in pregnant women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=see_link\">",
"      Infant of a diabetic mother",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=see_link\">",
"      Nutrition in pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35818?source=see_link\">",
"      Obstetrical management of pregnancy complicated by pregestational diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/19/21816?source=see_link\">",
"      Pregnancy in women with diabetic nephropathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42487?source=see_link\">",
"      Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/30/7657?source=see_link\">",
"      Recommendations for exercise during pregnancy and the postpartum period",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9210?source=see_link\">",
"      Screening and diagnosis of diabetes mellitus during pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37866?source=see_link\">",
"      Medical management and follow-up of gestational diabetes mellitus",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/diabetesandpregnancy.html\">",
"      www.nlm.nih.gov/medlineplus/diabetesandpregnancy.html",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.diabetes.niddk.nih.gov/dm/pubs/pregnancy/\">",
"      www.diabetes.niddk.nih.gov/dm/pubs/pregnancy/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Diabetes Association (ADA)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(800)-DIABETES (800-342-2383)",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.diabetes.org/gestational-diabetes/pregancy.jsp\">",
"      www.diabetes.org/gestational-diabetes/pregancy.jsp",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Endocrine Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.endo-society.org/\">",
"      www.endo-society.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hormone.org/public/diabetes.cfm\">",
"      www.hormone.org/public/diabetes.cfm",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?10/45/10966/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 1, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?10/45/10966?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10966/abstract/1\">",
"      American Diabetes Association. Preconception care of women with diabetes. Diabetes Care 2004; 27 Suppl 1:S76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10966/abstract/2\">",
"      Bell R, Glinianaia SV, Tennant PW, et al. Peri-conception hyperglycaemia and nephropathy are associated with risk of congenital anomaly in women with pre-existing diabetes: a population-based cohort study. Diabetologia 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10966/abstract/3\">",
"      McCance DR. Pregnancy and diabetes. Best Pract Res Clin Endocrinol Metab 2011; 25:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10966/abstract/4\">",
"      Mathiesen ER, Ringholm L, Damm P. Pregnancy management of women with pregestational diabetes. Endocrinol Metab Clin North Am 2011; 40:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10966/abstract/5\">",
"      American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care 2013; 36 Suppl 1:S11.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f10_45_10966=[""].join("\n");
var outline_f10_45_10966=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           IMPORTANCE OF BLOOD GLUCOSE CONTROL",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           CARE DURING PREGNANCY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           PLANNING FOR DELIVERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           INFANT CARE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           AFTER DELIVERY CARE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H23\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?6/10/6316\" title=\"table 1\">",
"           A1C and blood sugar PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f10_45_10967="Ketamine: Drug information";
var content_f10_45_10967=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ketamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/36/10820?source=see_link\">",
"    see \"Ketamine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"    see \"Ketamine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F185725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ketalar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F185726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ketalar&reg;;",
"     </li>",
"     <li>",
"      Ketamine Hydrochloride Injection, USP",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F185763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      General Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F185729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be used in combination with anticholinergic agents to decrease hypersalivation.",
"     <b>",
"      Note:",
"     </b>",
"     Titrate dose for desired effect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sedation/analgesia (unlabeled use):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 2-4 mg/kg (White, 1982)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 0.2-0.75 mg/kg (White, 1982)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous I.V. infusion: 2-7 mcg/kg/minute (Hocking, 2003; Rem&eacute;rand, 2009; Zakine, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Critically-ill patients: Loading dose: 0.1-0.5 mg/kg; followed by 0.83-6.7 mcg/kg/minute (equivalent to 0.05-0.4 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ) (Barr, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Induction of anesthesia (unlabeled dosing):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.:  4-10 mg/kg (Green, 1990; Miller, 2010; White, 1982)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 0.5-2 mg/kg (Miller, 2010; White, 1982)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Maintenance of anesthesia:",
"     </b>",
"     May administer supplemental doses of one-half to the full induction dose or a continuous infusion of 0.1-0.5 mg/minute (per manufacturer).",
"     <b>",
"      Note:",
"     </b>",
"     To maintain an adequate concentration of ketamine for maintenance of anesthesia, 1-2 mg/minute has been recommended (White, 1982); doses in the range of 15-90 mcg/kg/minute (~1-6 mg/minute in a 70-kg patient) have also been suggested (Miller, 2010). Concurrent use of nitrous oxide reduces ketamine requirements.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F185746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"      see \"Ketamine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be used in combination with anticholinergic agents to decrease hypersalivation.",
"     <b>",
"      Note:",
"     </b>",
"     Titrate dose for desired effect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sedation (unlabeled use):",
"     </b>",
"     Oral (unlabeled route): 5-8 mg/kg for 1 dose (mixed in 0.2-0.3 mL/kg of cola or other beverage) given 30 minutes before the procedure (Sacchetti, 1994; Rosenberg, 1991)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sedation/analgesia (unlabeled use):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 2-5 mg/kg/dose (Green, 2011; Krause, 2000; McGlone, 2004; White, 1982)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 0.5-1 mg/kg/dose (Sacchetti, 1994; Tobias, 1990)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous I.V. infusion: 5-20 mcg/kg/minute (White, 1982; Tobias, 1990)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Children &ge;16 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F185730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16160060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16160061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F185708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 10 mg/mL (20 mL); 50 mg/mL (10 mL); 100 mg/mL (5 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ketalar&reg;: 10 mg/mL (20 mL); 50 mg/mL (10 mL); 100 mg/mL (5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F185693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F185765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F185710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Mix the appropriate dose (using the 100 mg/mL injectable solution) in cola or other beverage; administer immediately after preparation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.V.: Administer bolus doses over 1 minute; more rapid administration may result in respiratory depression and enhanced pressor response.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F185770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Cefepime, ceftazidime, propofol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Bupivacaine, bupivacaine with fentanyl, clonidine, clonidine with tetracaine, dexamethasone sodium phosphate, fentanyl, lidocaine, lidocaine with morphine, meperidine, midazolam.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Diazepam, doxapram.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Morphine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F185709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Induction and maintenance of general anesthesia",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F5994625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Analgesia, sedation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F185772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ketalar&reg; may be confused with Kenalog&reg;, ketorolac",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F185761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, bradycardia/tachycardia, hyper-/hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Intracranial pressure increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythema (transient), morbilliform rash (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, nausea, salivation increased, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain at the injection site, exanthema at the injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Skeletal muscle tone enhanced (tonic-clonic movements)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Diplopia, intraocular pressure increased, nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Airway obstruction, apnea, bronchial secretions increased, respiratory depression, laryngospasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, dependence with prolonged use, emergence reactions (~12%; includes confusion, delirium, dreamlike state, excitement, hallucinations, irrational behavior, vivid imagery)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F185713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ketamine or any component of the formulation; conditions in which an increase in blood pressure would be hazardous",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F185697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). When used for outpatient surgery, the patient should be accompanied by a responsible adult.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dependence: May cause dependence (withdrawal symptoms on discontinuation) and tolerance with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Emergence reactions: Postanesthetic emergence reactions which can manifest as vivid dreams, hallucinations, and/or frank delirium occur; these reactions are less common in patients &lt;15 years of age and &gt;65 years and when given intramuscularly. Emergence reactions, confusion, or irrational behavior may occur up to 24 hours postoperatively and may be reduced by pretreatment with a benzodiazepine and the use of ketamine at the lower end of the dosing range.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory depression: Rapid I.V. administration or overdose may cause respiratory depression or apnea. Resuscitative equipment should be available during use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with coronary artery disease, catecholamine depletion, hypertension, and tachycardia. Cardiac function should be continuously monitored in patients with increased blood pressure or cardiac decompensation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebrospinal fluid (CSF) pressure elevation: Use with caution in patients with CSF pressure elevation; an increase in CSF pressure may be associated with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Use with caution in the chronic alcoholic or acutely alcohol-intoxicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician: Should be administered under the supervision of a physician experienced in administering general anesthetics.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F185759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2B6 (major), CYP2C9 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F185702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Moderate): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Strong): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quazepam: May increase the serum concentration of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5994626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Ketamine crosses the placenta and can be detected in fetal tissue. Ketamine produces dose dependent increases in uterine contractions; effects may vary by trimester. The plasma clearance of ketamine is reduced during pregnancy. Dose related neonatal depression and decreased APGAR scores have been reported with large doses administered at delivery.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ketalar Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (20 mL): $18.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (10 mL): $5.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (5 mL): $9.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ketamine HCl Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (20 mL): $17.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (10 mL): $5.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (5 mL): $9.78",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F185705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, blood pressure, respiratory rate, transcutaneous O",
"     <sub>",
"      2",
"     </sub>",
"     saturation, emergence reactions; cardiac function should be continuously monitored in patients with increased blood pressure or cardiac decompensation",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F185716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Anesject (ID);",
"     </li>",
"     <li>",
"      Brevinaze (ZA);",
"     </li>",
"     <li>",
"      Calypsol (AE, BB, BG, BH, BM, BS, BZ, CY, CZ, EG, GY, HN, HU, IQ, IR, JM, JO, KW, LB, LY, OM, PK, PL, PR, QA, RU, SA, SR, SY, TH, TT, YE);",
"     </li>",
"     <li>",
"      Ivanes (ID);",
"     </li>",
"     <li>",
"      Kanox (MY);",
"     </li>",
"     <li>",
"      Keiran (VE);",
"     </li>",
"     <li>",
"      Ketacor (PH);",
"     </li>",
"     <li>",
"      Ketalar (AE, AR, AU, BB, BE, BH, BM, BR, BS, BZ, CH, CY, DK, EE, EG, ES, FI, FR, GB, GR, GY, HK, ID, IE, IL, IN, IQ, IR, IT, JM, JO, KW, LB, LU, LY, MT, MY, NO, NZ, OM, PE, PT, QA, SA, SE, SK, SR, SY, TR, TT, TW, UY, YE);",
"     </li>",
"     <li>",
"      Ketalin (MX);",
"     </li>",
"     <li>",
"      Ketamax (PH);",
"     </li>",
"     <li>",
"      Ketamin-S (+) (PY);",
"     </li>",
"     <li>",
"      Ketanest (AT, HR, NL, PL);",
"     </li>",
"     <li>",
"      Ketashort (CO);",
"     </li>",
"     <li>",
"      Ketava (MY);",
"     </li>",
"     <li>",
"      Ketazol (PH);",
"     </li>",
"     <li>",
"      Ketmin (IN);",
"     </li>",
"     <li>",
"      Ketolar (ES);",
"     </li>",
"     <li>",
"      Narkamon (DE, PL);",
"     </li>",
"     <li>",
"      Soon-Soon (TW);",
"     </li>",
"     <li>",
"      Tekam (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Velonarcon (PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F185696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Produces a cataleptic-like state in which the patient is dissociated from the surrounding environment by direct action on the cortex and limbic system. Ketamine is a noncompetitive NMDA receptor antagonist that blocks glutamate. Low (subanesthetic) doses produce analgesia, and modulate central sensitization, hyperalgesia and opioid tolerance. Reduces polysynaptic spinal reflexes.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F185712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Anesthetic effect: 30 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Anesthetic effect: 3-4 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Anesthetic effect: I.V.: 5-10 minutes; I.M.: 12-25 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via hydroxylation and N-demethylation; the metabolite norketamine is 33% as potent as parent compound; greater conversion to norketamine occurs after oral administration as compared to parenteral administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 16%; Intranasal: 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Alpha: 10-15 minutes; Beta: 2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Adam F, Chauvin M, Du Manoir B, et al, \"Small-Dose Ketamine Infusion Improves Postoperative Analgesia and Rehabilitation After Total Knee Arthroplasty,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2005, 100(2):475-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/15673878/pubmed\" id=\"15673878\" target=\"_blank\">",
"        15673878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barr J, Fraser GL, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(1):263-306.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/23269131/pubmed\" id=\"23269131\" target=\"_blank\">",
"        23269131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clements JA and Nimmo WS, \"Pharmacokinetics and Analgesic Effect of Ketamine in Man,\"",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1981, 53(1):27-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/7459184/pubmed\" id=\"7459184\" target=\"_blank\">",
"        7459184",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cote CJ, \"Sedation for the Pediatric Patient: A Review,\"",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1994, 41(1):31-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/8295806/pubmed\" id=\"8295806\" target=\"_blank\">",
"        8295806",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Felser JM and Orban DJ, \"Dystonic Reaction After Ketamine Abuse,\"",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1982, 11(12):673-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/7149360/pubmed\" id=\"7149360\" target=\"_blank\">",
"        7149360",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghoneim MM and Korttila K, \"Pharmacokinetics of Intravenous Anaesthetics: Implications for Clinical Use,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1977, 2(5):344-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/21053/pubmed\" id=\"21053\" target=\"_blank\">",
"        21053",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glickman A, \"Ketamine: The Dissociative Anesthetic and the Development of a Policy for Its Safe Administration in the Pediatric Emergency Department,\"",
"      <i>",
"       J Emerg Nurs",
"      </i>",
"      , 1995, 21(2):116-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/7776601/pubmed\" id=\"7776601\" target=\"_blank\">",
"        7776601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Green SM and Johnson NE, \"Ketamine Sedation for Pediatric Procedures: Part 2, Review and Implications,\"",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1990, 19(9):1033-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/2203290/pubmed\" id=\"2203290\" target=\"_blank\">",
"        2203290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Green SM, Roback MG, Kennedy RM, et al, \"Clinical Practice Guideline for Emergency Department Ketamine Dissociative Sedation: 2011 Update,\"",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2011, 57(5):449-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/21256625/pubmed\" id=\"21256625\" target=\"_blank\">",
"        21256625",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guillou N, Tanguy M, Sequin P, et al, &ldquo;The Effects of Small-Dose Ketamine on Morphine Consumption in Surgical Intensive Care Unit Patients After Major Abdominal Surgery,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2003, 97(3):384-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/12933413/pubmed\" id=\"12933413\" target=\"_blank\">",
"        12933413",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gutstein HB, Johnson KL, Heard MN, et al, \"Oral Ketamine Premedication in Children,\"",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1992, 76(1):28-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/1729932/pubmed\" id=\"1729932\" target=\"_blank\">",
"        1729932",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hartvig P, Larsson E, and Joachimsson PO, \"Postoperative Analgesia and Sedation Following Pediatric Cardiac Surgery Using a Constant Infusion of Ketamine,\"",
"      <i>",
"       J Cardiothorac Vasc Anesth",
"      </i>",
"      , 1993, 7(2):148-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/8477017/pubmed\" id=\"8477017\" target=\"_blank\">",
"        8477017",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hartvig P, Valtysson J, Lindner KJ, et al, \"Central Nervous System Effects of Subdissociative Doses of (",
"      <i>",
"       S",
"      </i>",
"      )-Ketamine Are Related to Plasma and Brain Concentrations Measured With Positron Emission Tomography in Healthy Volunteers,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 58(2):165-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/7648766/pubmed\" id=\"7648766\" target=\"_blank\">",
"        7648766",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegenbarth MA and and the Committee on Drugs, \"Preparing for Pediatric Emergencies: Drugs to Consider,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121:433-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/18245435/pubmed\" id=\"18245435\" target=\"_blank\">",
"        18245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hocking G and Cousins MJ, \"Ketamine in Chronic Pain Management: An Evidence-Based Review,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2003, 97(6):1730-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/14633551/pubmed\" id=\"14633551\" target=\"_blank\">",
"        14633551",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kohrs R and Durieux ME, \"Ketamine: Teaching an Old Drug New Tricks,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1998, 87(5):1186-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/9806706/pubmed\" id=\"9806706\" target=\"_blank\">",
"        9806706",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Little B, Chang T, Chucot L, et al, \"Study of Ketamine as an Obstetric Anesthetic Agent,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 1972, 15:113(2):247-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/4554554/pubmed\" id=\"4554554\" target=\"_blank\">",
"        4554554",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Loftus RW, Yeager MP, Clark JA, et al, \"Intraoperative Ketamine Reduces Perioperative Opiate Consumption in Opiate-Dependent Patients With Chronic Back Pain Undergoing Back Surgery,\"",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 2010, 113(3):639-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/20693876/pubmed\" id=\"20693876\" target=\"_blank\">",
"        20693876",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marx GF, Hwang HS, and Chandra P, \"Postpartum Uterine Pressures With Different Doses of Ketamine,\"",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1979, 50(2):163-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/571254/pubmed\" id=\"571254\" target=\"_blank\">",
"        571254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McGlone RG, Howes MC, and Joshi M, \"The Lancaster Experience of 2.0 to 2.5 mg/kg Intramuscular Ketamine for Paediatric Sedation: 501 Cases and Analysis,\"",
"      <i>",
"       Emerg Med J",
"      </i>",
"      , 2004, 21(3):290-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/15107365/pubmed\" id=\"15107365\" target=\"_blank\">",
"        15107365",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mellon RD, Simone AF, and Rappaport BA, \"Use of Anesthetic Agents in Neonates and Young Children,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2007, 104(3):509-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/17312200/pubmed\" id=\"17312200\" target=\"_blank\">",
"        17312200",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Menigaux C, Fletcher D, Dupont X, et al, \"The Benefits of Intraoperative Small-Dose Ketamine on Postoperative Pain After Anterior Cruciate Ligament Repair,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2000, 90(1):129-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/10624993/pubmed\" id=\"10624993\" target=\"_blank\">",
"        10624993",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mercadante S, \"Ketamine in Cancer Pain: An Update,\"",
"      <i>",
"       Palliat Med",
"      </i>",
"      , 1996, 10(3):225-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/8817593/pubmed\" id=\"8817593\" target=\"_blank\">",
"        8817593",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller RD,",
"      <i>",
"       Miller&rsquo;s Anesthesia",
"      </i>",
"      ,  7th ed, Philadelphia PA: Churchill Livingstone, 2010.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moro-Sutherland DM and Shook JE, \"Ketamine Use in a Pediatric Emergency Room,\"",
"      <i>",
"       Acad Emerg Med",
"      </i>",
"      , 1995, 2:428-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mortero RF, Clark LD, Tolan MM, et al, \"The Effects of Small-Dose Ketamine on Propofol Sedation: Respiration, Postoperative Mood, Perception, Cognition, and Pain,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2001, 92(6):1465-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/11375826/pubmed\" id=\"11375826\" target=\"_blank\">",
"        11375826",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reeker W, Werner C, Mollenberg O, et al, \"High-Dose S(+)-ketamine Improves Neurological Outcome Following Incomplete Cerebral Ischemia in Rats,\"",
"      <i>",
"       Can J Anesth",
"      </i>",
"      , 2000, 47(6):572-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/10875722/pubmed\" id=\"10875722\" target=\"_blank\">",
"        10875722",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rem&eacute;rand F, Le Tendre C, Baud A, et al, \"The Early and Delayed Analgesic Effects of Ketamine After Total Hip Arthroplasty: A Prospective, Randomized, Controlled, Double-Blind Study,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2009, 109(6):1963-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/19923527/pubmed\" id=\"19923527\" target=\"_blank\">",
"        19923527",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenberg M, \"Oral Ketamine for Deep Sedation of Difficult-to-Manage Children Who are Mentally Handicapped: Case Report,\"",
"      <i>",
"       Pediatr Dent",
"      </i>",
"      , 1991, 13(4):221-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/1832219/pubmed\" id=\"1832219\" target=\"_blank\">",
"        1832219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sacchetti A, Schafermeyer R, Gerardi M, et al, \"Pediatric Analgesia and Sedation,\"",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1994, 23(2):237-50.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shannon M, \"Recent Ketamine Administration Can Produce a Urine Toxic Screen Which Is Falsely Positive for Phencyclidine,\"",
"      <i>",
"       Pediatr Emerg Care",
"      </i>",
"      , 1998, 14(2):180.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/9583407/pubmed\" id=\"9583407\" target=\"_blank\">",
"        9583407",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tobias JD and Rasmussen GE, \"Pain Management and Sedation in the Pediatric Intensive Care Unit,\"",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1994, 41(6):1269-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/7984386/pubmed\" id=\"7984386\" target=\"_blank\">",
"        7984386",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tobias JD, Martin LD, and Wetzel RC, \"Ketamine by Continuous Infusion for Sedation in the Pediatric Intensive Care Unit,\"",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1990, 18(8):819-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/2379394/pubmed\" id=\"2379394\" target=\"_blank\">",
"        2379394",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tobias JD, Phipps S, Smith B, et al, \"Oral Ketamine Premedication to Alleviate the Distress of Invasive Procedures in Pediatric Oncology Patients,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1992, 90(4):537-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/1408506/pubmed\" id=\"1408506\" target=\"_blank\">",
"        1408506",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      White PF, Way WL, and Trevor AJ, \"Ketamine &minus; Its Pharmacology and Therapeutic Uses,\"",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1982, 56(2):119-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/6892475/pubmed\" id=\"6892475\" target=\"_blank\">",
"        6892475",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Winters WD, \"Epilepsy or Anesthesia With Ketamine,\"",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1972, 36(4):309-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/5020639/pubmed\" id=\"5020639\" target=\"_blank\">",
"        5020639",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zakine J, Samarcq D, Lorne E, et al, \"Postoperative Ketamine Administration Decreases Morphine Consumption in Major Abdominal Surgery:  A Prospective, Randomized, Double-Blind, Controlled Study,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2008, 106(6):1856-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/45/10967/abstract-text/18499623/pubmed\" id=\"18499623\" target=\"_blank\">",
"        18499623",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8588 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-2.133.93.82-D9A3241E76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_45_10967=[""].join("\n");
var outline_f10_45_10967=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185725\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185726\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185763\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185729\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185746\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185730\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160060\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160061\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185708\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185693\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185765\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185710\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185770\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185709\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5994625\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185772\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185761\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185713\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185697\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185759\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185702\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5994626\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422244\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185705\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185716\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185696\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185712\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8588\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8588|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/36/10820?source=related_link\">",
"      Ketamine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=related_link\">",
"      Ketamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_45_10968="Proton and ion beams in cancer therapy";
var content_f10_45_10968=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Proton and ion beams in cancer therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/45/10968/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/45/10968/contributors\">",
"     Jeffrey J Meyer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/45/10968/contributors\">",
"     Andrew K Lee, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/45/10968/contributors\">",
"     Thomas F DeLaney, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/45/10968/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/45/10968/contributors\">",
"     Brian Kavanagh, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/45/10968/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/45/10968/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/45/10968/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (RT) plays an essential role in the management of many patients with cancer. Most modern RT techniques use megavoltage x-rays (photons) or electrons.",
"   </p>",
"   <p>",
"    Attempts to improve the antitumor efficacy of x-ray RT as well as to reduce the toxicity associated with its use have taken many forms over the past few decades. Examples include CT-based 3D-conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT), and stereotactic and image-guidance techniques.",
"   </p>",
"   <p>",
"    There is considerable interest in the use of high energy protons, as well as heavier particles, such as carbon ions, for cancer therapy, based upon the appealing physical properties of these particles. The use of protons and beams of heavier ions in cancer therapy is discussed in this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE FOR CLINICAL ADVANTAGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As charged particles travel through tissue, they gradually decelerate and transfer energy to tissues, resulting in molecular excitations and ionizations. A sharp rise in energy transfer, termed the Bragg peak, takes place near the end of the finite range of the particle (",
"    <a class=\"graphic graphic_figure graphicRef53348 \" href=\"UTD.htm?36/18/37153\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For protons, the radiation dose beyond the Bragg peak sharply drops to zero, resulting in no radiation beyond this point (exit dose). For heavier charged particles (such as carbon ions), there is a trail of low radiation dose distal to the Bragg peak secondary to continued energy deposition from charged nuclear fragment by-products [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/2\">",
"     2",
"    </a>",
"    ]. Because the Bragg peak is narrow, particle energies are modulated during most treatments, with the peaks summing to generate a broader \"spread-out\" Bragg peak (SOBP) (",
"    <a class=\"graphic graphic_figure graphicRef53348 \" href=\"UTD.htm?36/18/37153\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In both cases, dose deposition differs dramatically from x-ray irradiation, in which the peak dose is relatively superficial in tissue followed by a gradual fall-off in dose. As a result, the exit dose through normal tissues with x-ray irradiation can be substantial.",
"   </p>",
"   <p>",
"    Proton radiobiology is similar to that of x-ray radiobiology. The International Commission on Radiation Units and Measurements has recommended that doses be expressed as Gy (RBE) (relative biological effectiveness) for reporting purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/3\">",
"     3",
"    </a>",
"    ]. A correction factor of 1.1 is often generically used to convert doses; that is, 1 Gy of physical dose delivered with protons is biologically equivalent to 1.1 Gy delivered with x-rays (formerly termed Cobalt-60 Gy equivalents [CGE]).",
"   </p>",
"   <p>",
"    The potentially lower dose to non-target structures and the consequent reduction in acute and late toxicity is the primary appeal of charged particle therapy. This reduced toxicity may improve the tolerability of therapy, including regimens that incorporate chemotherapy. In younger patients, a low integral dose to normal tissue (protons reduce the total radiation dose to normal tissue by approximately 60 percent) may decrease the likelihood of growth retardation and second malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The reduced toxicity may also allow for escalation of the total radiation dose.",
"   </p>",
"   <p>",
"    Multiple treatment fields, often employing intensity modulation, are used to overcome the physical limitations of x-rays. Proton and carbon ion treatments often can maintain conformality to the target while using a more limited number of fields, with a cumulative dose to normal tissues that is significantly lower (approximately 60 percent) than that seen with x-rays. Active beam scanning technology and the application of intensity modulation methods can be used to increase the conformality of particle radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With proton irradiation, the biological effect may become more pronounced near the distal edge of the Bragg peak, as ionization density increases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/7\">",
"     7",
"    </a>",
"    ]. Carbon ions, in contrast, are more densely ionizing radiation and have fluctuating RBE values over the course of the beam in tissue and its spread out Bragg peak [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/2\">",
"     2",
"    </a>",
"    ]. If beams are designed properly, the RBE is relatively low in the normal tissues proximal to the peak region and high within the tumor itself. Densely ionizing particles are less sensitive to hypoxia and cell cycle state compared to x-rays and protons. Thus, carbon ion irradiation offers the advantages of the Bragg peak as well as higher biologic potency relative to protons and x-rays. However, it remains uncertain whether there is a true differential biologic effect on tumor compared to normal tissue (ie, a therapeutic advantage) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CHALLENGES WITH PROTON AND ION BEAM RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Particle therapy use in clinical oncology was initially proposed in the 1940s [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/1\">",
"     1",
"    </a>",
"    ]. In the 1950s, charged particle therapy was initiated at the Lawrence Berkeley laboratory, in Uppsala, Sweden, and at the Harvard Cyclotron [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. The first hospital-based proton facility, at Loma Linda University, began treating patients in the early 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/12\">",
"     12",
"    </a>",
"    ]. This technology is now becoming available at a number of hospital-based facilities that are often built and supported by commercial vendors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cost effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increasing interest in particle therapy has been accompanied by a controversy over its appropriate role in clinical oncology because of its higher cost [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Because protons are 1800 times heavier than electrons, accelerating and delivering them to the patient requires higher energies and heavier magnets than photon linear accelerators that employ electron accelerators. Thus, heavy ion particle accelerators are significantly more costly to build and maintain. There are emerging technologies that may allow for less expensive access to particle treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether or not these theoretical advantages of proton and heavy ion RT will translate into genuine clinical benefits remains uncertain. There are no results from randomized clinical trials comparing this approach with other contemporary external beam RT techniques.",
"   </p>",
"   <p>",
"    A number of issues may limit the fulfillment of this approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are two major sources of uncertainty that limit the ability to calculate precisely the actual depth of the Bragg peak in patients receiving proton therapy. First, there is some modest uncertainty in converting CT Hounsfield units to proton stopping powers at some tissue densities. Secondly, for the variable types of human tissue through which the protons will travel, there is uncertainty concerning the mean excitation energy or I-value, a physical parameter that determines the depth of energy deposition. [",
"      <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/16\">",
"       16",
"      </a>",
"      ]. Net range uncertainty can be on the order of 1 cm in some situations where high density structures are adjacent to air-containing cavities. These problems are compounded by additional uncertainty in the biological effects of particles at or near the end of their range. Developments in treatment planning using Monte Carlo simulations should reduce the uncertainty in these situations [",
"      <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Particles are very sensitive to changes in density of the tissues through which they travel (the radiologic path length); thus, organ motion and errors in patient set-up need to be considered in the treatment planning process. There are various means of accounting for these issues, but these measures degrade the conformality that may be achieved with particle therapy.",
"     </li>",
"     <li>",
"      Proton irradiation can yield neutron contamination as a result of collisions of the protons with structures in the beam path as well as interactions in the patient's tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/18\">",
"       18",
"      </a>",
"      ]. Neutrons are capable of inducing DNA damage and transforming cells. Neutron-induced second malignancies are thus a possibility in proton therapy (as well as in high energy x-ray therapy). Estimates of the likelihood of neutron-induced tumors produced by proton therapy have varied [",
"      <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result of these issues, highly conformal IMRT can actually yield improved sparing of normal tissues in the high-dose range compared with currently available 3-D proton technology. In the mid-to-lower dose range, protons yield a higher degree of sparing, and the total (integral) dose to normal tissues seen with protons is less than that seen with x-rays [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/19\">",
"     19",
"    </a>",
"    ]. Intensity modulated proton therapy may yield similar dose conformality to IMRT with substantial reduction in the irradiation dose to normal tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL RESULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;To date, there is a relative lack of clinical data regarding relative treatment efficacy and toxicity. The following sections provide an overview of what is known regarding efficacy and toxicity of protons and ion beam therapy for selected common tumor sites, as well as for the impact on the incidence of second malignancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lung cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main dose-limiting toxicities with RT for lung cancer are esophagitis acutely and pneumonitis and cardiac damage in the long-term.",
"   </p>",
"   <p>",
"    Lung parenchyma is highly sensitive to the effects of radiation. High doses to limited volumes can be safely delivered with stereotactic and image-guided approaches. However, treatment of more advanced, centrally located, and high-volume disease requires very careful consideration of dose-volume relationships, especially when chemotherapy is also used in the treatments. Proton therapy offers theoretical dose-sparing benefits compared to x-ray therapy, potentially reducing pneumonitis rates and allowing better tolerability of concurrent chemoirradiation regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H167676282\">",
"    <span class=\"h3\">",
"     Protons",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous studies have reported experience with protons for the treatment of non-small cell lung cancer (NSCLC) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. In the largest of these series, 68 patients with T1N0 or T2N0 disease were treated with hypofractionated proton therapy. Doses ranged from 51 to 60 Gy RBE divided into 10 fractions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/21\">",
"     21",
"    </a>",
"    ]. Three-year local control rates for the T1 and T2 tumors were 87 and 49 percent, respectively. There were no cases of symptomatic radiation pneumonitis.",
"   </p>",
"   <p>",
"    Contemporary stereotactic and image-guided hypofractionated x-ray therapy approaches have yielded similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/25\">",
"     25",
"    </a>",
"    ]. Additional experience and longer follow-up is necessary before an appropriate comparison of particle therapy and definitive x-ray therapy is possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/5/1114?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of stage I and stage II non-small cell lung cancer\", section on 'Definitive RT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dosimetric advantages of protons over x-ray therapy in the treatment of patients with mediastinal nodal involvement have been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/26\">",
"     26",
"    </a>",
"    ]. Studies incorporating proton therapy and concurrent chemotherapy for locally advanced disease are underway. Early clinical data suggest that the rate of pneumonitis is lower than that with photon-based therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/27\">",
"     27",
"    </a>",
"    ]. A randomized comparison of IMRT and proton therapy for patients with lung cancer is in progress in a multi-institutional study currently underway at M D Anderson Cancer Center and Massachusetts General Hospital (NCT00915005) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H167676289\">",
"    <span class=\"h3\">",
"     Carbon ions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    study from the National Institute of Radiological Sciences (Chiba) used carbon ion irradiation to treat 50 patients with stage I peripheral NSCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/29\">",
"     29",
"    </a>",
"    ]. In an analysis of patients treated at a dose of 72 Gy RBE in nine fractions over three weeks, the five-year local control rate was 95 percent with a median follow-up of almost five years. There were no grade 3 or higher late lung toxicities; two of 50 assessable patients developed late grade 2 lung toxicity.",
"   </p>",
"   <p>",
"    A subsequent study in 76 patients used a dose of 52.8 GyE in four fractions for T1N0 tumors and 60 GyE in four fractions for T2N0 tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/30\">",
"     30",
"    </a>",
"    ]. Local control rates for T1 and T2 tumors were 98 and 80 percent, respectively, at a median follow-up of over three years. One patient developed late grade 2 lung toxicity. The initial results have been published from a single fraction dose-escalation study initiated in April 2003. The initial dose was 28.0 GyE, with the total irradiation dose being escalated in increments of 2.0 GyE, up to 44.0 GyE. The preliminary data suggest favorable local control and very few toxic reactions with a median follow up time of about 16 months. For skin reactions, only one grade 2 toxicity was reported, and no grade 3 or higher toxicity was observed. For radiation pneumonitis, only one grade 1 event was reported, and no toxicities greater than grade 2 occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/31\">",
"     31",
"    </a>",
"    ]. More central lesions are being treated in an ongoing phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    study with a fractionated regimen of twelve fractions to 64.8 GyRBE [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hepatocellular cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical intervention is the treatment of choice for hepatocellular cancer (HCC). In patients who are poor operative candidates, there are a number of ablative treatment options.",
"   </p>",
"   <p>",
"    Radiation has traditionally held a minor role in treating HCC, as the liver is a highly radiosensitive structure. However, small volumes can be treated to high doses so long as there is reasonable sparing of the remaining parenchyma. As a result, there has been interest in using the normal-tissue sparing properties of charged particle irradiation to deliver high doses of radiation to hepatocellular cancers (particularly in the setting of portal vein thrombus) as well as tumors metastatic to the liver. These data are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36138?source=see_link\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cancer of the head and neck",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucosal toxicity and xerostomia are often significant problems during RT of head and neck malignancies. IMRT has been introduced to minimize this toxicity. Charged particle therapy may offer an alternative to IMRT, especially when employed in the boost portion of therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Protons &mdash; The Loma Linda University group reported on 29 patients with stage II to IV oropharyngeal cancer, in whom protons were utilized in the boost portion of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/32\">",
"       32",
"      </a>",
"      ]. Total dose to the primary tumor was 75.9 Gy RBE, which was delivered in 45 fractions over 5.5 weeks. Control of disease in the head and neck was 84 percent at five years, while the two-year actuarial incidence of late grade 3 toxicity was 16 percent. These tumor control results are superior to historical controls, although additional experience and longer follow-up are required.",
"     </li>",
"     <li>",
"      Carbon ions &mdash; In a retrospective study, improved locoregional control rates without an increase in toxicity was reported in 29 patients with adenoid cystic carcinomas of the head and neck, using high doses of combined x-ray and carbon ion irradiation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28313?source=see_link\">",
"       \"Salivary gland tumors: Treatment of locoregional disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cervical cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concurrent cisplatin-based chemotherapy and external beam RT, typically in conjunction with a brachytherapy boost, are standard treatment for patients with locally advanced cervical cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22570?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of radiation therapy for gynecologic malignancies\", section on 'Cervical cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Protons &mdash; Protons offer a potential alternative to intracavitary brachytherapy applications because of their excellent dose distributions. In a Japanese series, 25 patients with stage IIB-IVA squamous cell carcinoma of the cervix were treated with external beam x-ray therapy to the primary tumor and pelvis, combined with a proton boost [",
"      <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/35\">",
"       35",
"      </a>",
"      ]. The median combined dose to the primary tumor was 81 Gy. Five-year local control rates were 100 percent for the patients with stage IIB disease and 61 percent for those with IIIB or IVA disease. The crude incidence of grade 3 to 4 late intestine and bladder injury was 4 percent.",
"     </li>",
"     <li>",
"      Carbon ions &mdash; Hypoxia is a negative prognostic and predictive factor in cervical cancer treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/36\">",
"       36",
"      </a>",
"      ]. Carbon ion therapy is less dependent upon the presence of oxygen for cell kill and thus has potential biological advantages over x-ray and proton therapy in the treatment of poorly oxygenated cervical tumors.",
"      <br/>",
"      <br/>",
"      In Japanese phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      clinical studies using carbon ion therapy in patients with stage IIIB or IVA cervical cancer, a pelvic radiation dose of 44.8 GyE (2.8 GyE per fraction) was combined with a boost of 24 or 28 GyE to the primary tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/37\">",
"       37",
"      </a>",
"      ]. The five-year local control rate for these patients was 79 percent. Severe (grade 4) toxicity was seen when portions of the gastrointestinal tract received &gt;60 GyE, and this was used as a limiting dose toward the end of the study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Renal cell cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection remains the standard of care approach to localized renal cell cancer. Nephron-sparing techniques are being developed for use in patients with compromised renal function and for those who are not surgical candidates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5546?source=see_link\">",
"     \"Surgical management of localized renal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26310?source=see_link\">",
"     \"Radiofrequency ablation and cryoablation for renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A Japanese group treated ten patients with localized renal cell cancer treated with carbon ion irradiation, with doses ranging from 64 to 80 GyE, in 16 fractions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/38\">",
"     38",
"    </a>",
"    ]. The median maximum tumor dimension was 4.3 cm. Five-year actuarial local control and cause-specific survival were 100 percent. No patient developed distant metastasis. One patient developed grade 4 skin toxicity, probably as a result of the proximity of the locally invasive tumor to the skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prostate cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;In men with prostate cancer, modeling studies have shown that three-dimensional conformal therapy using protons spares normal tissues better than IMRT in the low-to-mid dose range, although IMRT may offer a slight benefit in the high-dose range [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/19\">",
"     19",
"    </a>",
"    ]. To date, clinical studies have shown only limited improvement, if any, in toxicity profiles, although comparisons between nonrandomized series are inherently difficult. No randomized trials are currently underway.",
"   </p>",
"   <p>",
"    Intensity modulated proton therapy (IMPT) using scanned proton beams will have dose conformality similar to IMRT with substantially lower integral radiation dose to the pelvis, but IMPT is not currently employed at most proton centers and will require very careful control of the proton range with techniques such as a rectal dosimeter.",
"   </p>",
"   <p>",
"    Protons may have benefits in treating prostate cancer for the two following reasons. First, there is the expected reduction in normal tissue integral dose, which may be important in preventing radiation-induced second malignancies, particularly in younger men [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/39\">",
"     39",
"    </a>",
"    ]. Secondly, escalation of dose to focal lesions within the prostate may be more feasible with protons compared with x-ray therapy.",
"   </p>",
"   <p>",
"    As for the use of heavier ions, the interest in carbon ion therapy is rooted at least partially in the history of neutron therapy for prostate cancer. Previous clinical trials have demonstrated potential benefits of neutron treatments for locally advanced prostate tumors, although with high rates of toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/40\">",
"     40",
"    </a>",
"    ]. Carbon ions have a radiobiological profile similar to neutrons, but with the added benefit of improved depth-dose profiles.",
"   </p>",
"   <p>",
"    The clinical experience with particle therapy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=see_link&amp;anchor=H9#H9\">",
"     \"External beam radiation therapy for localized prostate cancer\", section on 'Particle irradiation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Bone and soft tissue sarcomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inoperable bone and soft tissue sarcomas can be a particular challenge because of their proximity to vital structures. RT can offer an alternative approach when surgical resection is not feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Protons &mdash; The potential role of combined photon proton therapy was illustrated by a series of 50 patients with spine sarcomas [",
"      <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/42\">",
"       42",
"      </a>",
"      ]. Treatment included surgery",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chemotherapy in some cases. Local control was achieved in 41 of 50 patients, including 34 of 36 patients treated for primary (as opposed to locally recurrent after prior surgery) tumors with an acceptable morbidity profile.",
"     </li>",
"     <li>",
"      Carbon ions &mdash; The group at Chiba used carbon ion therapy to treat 57 patients (64 tumors) with unresectable sarcomas of bone and soft tissue in a phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      study [",
"      <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/43\">",
"       43",
"      </a>",
"      ]. Using total doses of 52.8 to 73.6 GyE in 16 fractions (3.3 to 4.6 GyE per fraction), the three-year local control was 73 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pediatric malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential benefits of proton therapy are probably greatest in pediatric cancer patients. In theory, the reduced radiation exposure of normal tissues will yield lower rates of radiation-induced second malignancies, as well as less damage to developing organs. Pediatric tumors that arise in and near critical structures are well suited to the use of proton treatment; these include gliomas, medulloblastomas, retinoblastomas, rhabdomyosarcomas, and pelvic sarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a modeling study, the risk of second malignancy in children undergoing conventional or intensity-modulated x-ray therapy was compared with conventional or intensity-modulated proton therapy for the treatment of medulloblastoma and parameningeal rhabdomyosarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/4\">",
"     4",
"    </a>",
"    ]. For medulloblastoma, there was an 8- to 15-fold decrease in risk of developing a radiation-induced malignancy; for rhabdomyosarcoma, the expected reduction was about twofold. Neutron contamination was not modeled in this study.",
"   </p>",
"   <p>",
"    Preliminary evidence supporting a decreased incidence of second malignancies in patients treated with particle irradiation is discussed below. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Second malignancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Melanoma",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Uveal melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the first clinical settings in which particle therapy was evaluated was for patients with uveal melanomas. Currently, there are multiple potential treatments for small uveal melanomas, including plaque brachytherapy, stereotactic x-ray irradiation, and proton and heavier ion irradiation.",
"   </p>",
"   <p>",
"    Where facilities and expertise are available, charged particle therapy is the treatment of choice for larger uveal melanomas, which cannot be managed with plaque brachytherapy. The data supporting the use of this approach is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/59/8122?source=see_link&amp;anchor=H9#H9\">",
"     \"Ocular melanoma\", section on 'Charged particle irradiation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Mucosal melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection is the standard approach to melanomas arising in the head and neck. When surgery is not feasible, RT has been used as an alternative to provide local control. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4010?source=see_link&amp;anchor=H3306310#H3306310\">",
"     \"Mucosal melanoma\", section on 'Mucosal melanoma of the head and neck'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8713?source=see_link&amp;anchor=H6#H6\">",
"     \"Role of radiation therapy in the management of melanoma\", section on 'RT alone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a series from Chiba, carbon ion RT was used to treat 72 patients with mucosal melanoma of the head and neck [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/47\">",
"     47",
"    </a>",
"    ]. At a median follow-up of 49 months, the five-year local control rate and cause-specific survival rate were 84 and 40 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Chordomas and chondrosarcomas of the skull base",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumors involving the skull base are difficult to manage as a result of their proximity to critical neural structures. Maximum surgical resection is the mainstay of therapy, but complete resections are difficult to achieve.",
"   </p>",
"   <p>",
"    Adjuvant radiotherapy is commonly employed, but traditionally it has been difficult to apply tumoricidal doses (&gt;70 Gy RBE) of radiation, especially with conventional 2D- and 3D-radiation therapy as a result of risks of damaging the brainstem and cranial nerves. Multiple retrospective series have shown the relatively safe use of proton therapy for treating residual skull base tumors to high doses. The results of these studies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7815?source=see_link\">",
"     \"Chordoma and chondrosarcoma of the skull base\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, an analysis by the M D Anderson group suggested that the radiation dose distribution achieved by the use of proton beam alone in the treatment of chordoma can be rivaled by that achieved with photon IMRT alone or a mixture of photons and protons [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/48\">",
"     48",
"    </a>",
"    ]. It should be noted that many of the results in the literature are in fact combinations of photons and protons, and until intensity modulated protons are available, there may be advantages to the combination of intensity modulated photons of 20 to 30 Gy with protons, taking advantage of the higher conformality of IMRT and the reduction of integral dose with protons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Second malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A decreased risk of second malignancy following RT is an important potential benefit of proton beam irradiation, particularly in children. Long-term follow-up will be required to accurately determine the extent to which this benefit is realized.",
"   </p>",
"   <p>",
"    A preliminary report compared the incidence of second malignancies seen in 503 patients treated with proton therapy at the Harvard Cyclotron to a matched cohort of 1591 patients derived from the SEER database who had been treated with photons [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10968/abstract/5\">",
"     5",
"    </a>",
"    ]. Second malignancies were significantly more frequent in patients treated with photons rather than protons (12.8 versus 6.4 percent, hazard ratio 2.73, 95% CI 1.87-3.98). This observation requires confirmation in additional studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proton and heavy ion therapy are alternatives to conventional x-ray-based radiation therapy. Rational incorporation of technologies that have been used to improve modern x-ray therapy, such as use of image guidance, will bolster the strengths of proton therapy in the upcoming years.",
"   </p>",
"   <p>",
"    For certain tumor sites, such as large uveal melanomas, select skull base tumors, and select pediatric malignancies, particle therapy is largely accepted as standard of care treatment. The role of particle therapy in treating other sites, such as prostate cancer, remains more controversial, and has been the subject of intense scrutiny in the oncology community, mostly over questions of cost-effectiveness. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Challenges with proton and ion beam RT'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Randomized comparisons of charged particle therapy versus conventional x-ray treatment are needed to better define the relative benefits of these approaches. Such trials may be feasible for certain sites and less feasible for others. In the absence of randomized trials, well-conducted prospective registry studies are necessary to allow a realistic assessment of the benefits of charged particle therapy.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/1\">",
"      WILSON RR. Radiological use of fast protons. Radiology 1946; 47:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/2\">",
"      Kr&auml;mer M, Weyrather WK, Scholz M. The increased biological effectiveness of heavy charged particles: from radiobiology to treatment planning. Technol Cancer Res Treat 2003; 2:427.",
"     </a>",
"    </li>",
"    <li>",
"     Prescribing, recording, and reporting proton-beam therapy ICRU report. In: 2007 Series: Journal of the ICRY 7(2), No. 78, International Commission on Radiation Units and Measurements (Ed), Oxford University Press, Bethesda, MD 2007. p.210 pages.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/4\">",
"      Miralbell R, Lomax A, Cella L, Schneider U. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys 2002; 54:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/5\">",
"      Chung, CS, Keating, N, Yock, T, Tarbell, N. Comparative analysis of secondary malignancy risk in patients treated with proton therapy versus conventional photon therapy (abstract). Int J Radiat Oncol Biol Phys 2008; 72:S8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/6\">",
"      Lomax AJ, Boehringer T, Coray A, et al. Intensity modulated proton therapy: a clinical example. Med Phys 2001; 28:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/7\">",
"      Robertson JB, Williams JR, Schmidt RA, et al. Radiobiological studies of a high-energy modulated proton beam utilizing cultured mammalian cells. Cancer 1975; 35:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/8\">",
"      Wilkens JJ, Oelfke U. Direct comparison of biologically optimized spread-out bragg peaks for protons and carbon ions. Int J Radiat Oncol Biol Phys 2008; 70:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/9\">",
"      Castro JR. Results of heavy ion radiotherapy. Radiat Environ Biophys 1995; 34:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/10\">",
"      FALKMER S, FORS B, LARSSON B, et al. Pilot study on proton irradiation of human carcinoma. Acta radiol 1962; 58:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/11\">",
"      Kjellberg RN, Shintani A, Frantz AG, Kliman B. Proton-beam therapy in acromegaly. N Engl J Med 1968; 278:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/12\">",
"      Slater JD. Development and operation of the Loma Linda University Medical Center proton facility. Technol Cancer Res Treat 2007; 6:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/13\">",
"      Konski A, Speier W, Hanlon A, et al. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol 2007; 25:3603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/14\">",
"      Suit H, Kooy H, Trofimov A, et al. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No. Radiother Oncol 2008; 86:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/15\">",
"      Hede K. Research groups promoting proton therapy \"lite\". J Natl Cancer Inst 2006; 98:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/16\">",
"      Andreo P. On the clinical spatial resolution achievable with protons and heavier charged particle radiotherapy beams. Phys Med Biol 2009; 54:N205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/17\">",
"      Paganetti H, Jiang H, Parodi K, et al. Clinical implementation of full Monte Carlo dose calculation in proton beam therapy. Phys Med Biol 2008; 53:4825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/18\">",
"      Brenner DJ, Hall EJ. Secondary neutrons in clinical proton radiotherapy: a charged issue. Radiother Oncol 2008; 86:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/19\">",
"      Trofimov A, Nguyen PL, Coen JJ, et al. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys 2007; 69:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/20\">",
"      Weber DC, Trofimov AV, Delaney TF, Bortfeld T. A treatment planning comparison of intensity modulated photon and proton therapy for paraspinal sarcomas. Int J Radiat Oncol Biol Phys 2004; 58:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/21\">",
"      Bush DA, Slater JD, Shin BB, et al. Hypofractionated proton beam radiotherapy for stage I lung cancer. Chest 2004; 126:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/22\">",
"      Hata M, Tokuuye K, Kagei K, et al. Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study. Int J Radiat Oncol Biol Phys 2007; 68:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/23\">",
"      Nihei K, Ogino T, Ishikura S, Nishimura H. High-dose proton beam therapy for Stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006; 65:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/24\">",
"      Shioyama Y, Tokuuye K, Okumura T, et al. Clinical evaluation of proton radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003; 56:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/25\">",
"      Lo SS, Fakiris AJ, Papiez L, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer. Expert Rev Anticancer Ther 2008; 8:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/26\">",
"      Chang JY, Zhang X, Wang X, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006; 65:1087.",
"     </a>",
"    </li>",
"    <li>",
"     Cox, JD, Sejpal, S, Komaki, R, et al. Proton therapy with concurrent chemotherapy can reduce toxicity and allow higher radiation doses in advanced non-small cell lung cancer. 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology. Abstract.",
"    </li>",
"    <li>",
"     National Institutes of Health Clinical trials database. file://www.clinicaltrials.gov/ (Accessed on November 23, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/29\">",
"      Miyamoto T, Baba M, Yamamoto N, et al. Curative treatment of Stage I non-small-cell lung cancer with carbon ion beams using a hypofractionated regimen. Int J Radiat Oncol Biol Phys 2007; 67:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/30\">",
"      Miyamoto T, Baba M, Sugane T, et al. Carbon ion radiotherapy for stage I non-small cell lung cancer using a regimen of four fractions during 1 week. J Thorac Oncol 2007; 2:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/31\">",
"      Okada T, Kamada T, Tsuji H, et al. Carbon ion radiotherapy: clinical experiences at National Institute of Radiological Science (NIRS). J Radiat Res 2010; 51:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/32\">",
"      Slater JD, Yonemoto LT, Mantik DW, et al. Proton radiation for treatment of cancer of the oropharynx: early experience at Loma Linda University Medical Center using a concomitant boost technique. Int J Radiat Oncol Biol Phys 2005; 62:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/33\">",
"      Schulz-Ertner D, Nikoghosyan A, Didinger B, et al. Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques. Cancer 2005; 104:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/34\">",
"      Eifel PJ. Chemoradiotherapy in the treatment of cervical cancer. Semin Radiat Oncol 2006; 16:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/35\">",
"      Kagei K, Tokuuye K, Okumura T, et al. Long-term results of proton beam therapy for carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 2003; 55:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/36\">",
"      Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 2004; 9 Suppl 5:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/37\">",
"      Kato S, Ohno T, Tsujii H, et al. Dose escalation study of carbon ion radiotherapy for locally advanced carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 2006; 65:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/38\">",
"      Nomiya T, Tsuji H, Hirasawa N, et al. Carbon ion radiation therapy for primary renal cell carcinoma: initial clinical experience. Int J Radiat Oncol Biol Phys 2008; 72:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/39\">",
"      Fontenot JD, Lee AK, Newhauser WD. Risk of secondary malignant neoplasms from proton therapy and intensity-modulated x-ray therapy for early-stage prostate cancer. Int J Radiat Oncol Biol Phys 2009; 74:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/40\">",
"      Russell KJ, Caplan RJ, Laramore GE, et al. Photon versus fast neutron external beam radiotherapy in the treatment of locally advanced prostate cancer: results of a randomized prospective trial. Int J Radiat Oncol Biol Phys 1994; 28:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/41\">",
"      Kepka L, DeLaney TF, Suit HD, Goldberg SI. Results of radiation therapy for unresected soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 2005; 63:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/42\">",
"      DeLaney TF, Liebsch NJ, Pedlow FX, et al. Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys 2009; 74:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/43\">",
"      Kamada T, Tsujii H, Tsuji H, et al. Efficacy and safety of carbon ion radiotherapy in bone and soft tissue sarcomas. J Clin Oncol 2002; 20:4466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/44\">",
"      Lee CT, Bilton SD, Famiglietti RM, et al. Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques? Int J Radiat Oncol Biol Phys 2005; 63:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/45\">",
"      Yuh GE, Loredo LN, Yonemoto LT, et al. Reducing toxicity from craniospinal irradiation: using proton beams to treat medulloblastoma in young children. Cancer J 2004; 10:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/46\">",
"      McAllister B, Archambeau JO, Nguyen MC, et al. Proton therapy for pediatric cranial tumors: preliminary report on treatment and disease-related morbidities. Int J Radiat Oncol Biol Phys 1997; 39:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/47\">",
"      Yanagi T, Mizoe JE, Hasegawa A, et al. Mucosal malignant melanoma of the head and neck treated by carbon ion radiotherapy. Int J Radiat Oncol Biol Phys 2009; 74:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10968/abstract/48\">",
"      Torres MA, Chang EL, Mahajan A, et al. Optimal treatment planning for skull base chordoma: photons, protons, or a combination of both? Int J Radiat Oncol Biol Phys 2009; 74:1033.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7065 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-4DCBBA35C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_45_10968=[""].join("\n");
var outline_f10_45_10968=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE FOR CLINICAL ADVANTAGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CHALLENGES WITH PROTON AND ION BEAM RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cost effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical disadvantages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL RESULTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lung cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H167676282\">",
"      - Protons",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H167676289\">",
"      - Carbon ions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hepatocellular cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cancer of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Renal cell cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Bone and soft tissue sarcomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pediatric malignancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Melanoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Uveal melanoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Mucosal melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Chordomas and chondrosarcomas of the skull base",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Second malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7065\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7065|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/18/37153\" title=\"figure 1\">",
"      Spread out Bragg peak",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7815?source=related_link\">",
"      Chordoma and chondrosarcoma of the skull base",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=related_link\">",
"      External beam radiation therapy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/5/1114?source=related_link\">",
"      Management of stage I and stage II non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4010?source=related_link\">",
"      Mucosal melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36138?source=related_link\">",
"      Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/59/8122?source=related_link\">",
"      Ocular melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22570?source=related_link\">",
"      Overview of radiation therapy for gynecologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26310?source=related_link\">",
"      Radiofrequency ablation and cryoablation for renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8713?source=related_link\">",
"      Role of radiation therapy in the management of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28313?source=related_link\">",
"      Salivary gland tumors: Treatment of locoregional disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5546?source=related_link\">",
"      Surgical management of localized renal cell carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_45_10969="Use of recombinant hematopoietic growth factors in stem cell and progenitor cell mobilization";
var content_f10_45_10969=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of recombinant hematopoietic growth factors in stem cell and progenitor cell mobilization",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/45/10969/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/45/10969/contributors\">",
"     Colin A Sieff, MB, BCh, FRCPath",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/45/10969/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/45/10969/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/45/10969/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/45/10969/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/45/10969/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of hematopoietic progenitor cells from the peripheral blood provides an attractive alternative to the use of bone marrow cells for transplantation, and is currently used in both autologous and allogeneic settings. This approach requires harvesting of primitive stem cells from the peripheral circulation, usually identified as CD34+ cells. Although stem cells with the capacity to reconstitute hematopoiesis after transplantation comprise only a tiny proportion of CD34+ cells, a large volume of clinical data supports the concept that CD34 expression and the number of CD34+ cells infused correlate closely with the pace of hematopoietic reconstitution in both animals and humans.",
"   </p>",
"   <p>",
"    Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) can be used to mobilize a mixture of stem and other cells from the bone marrow, and these cells are referred to as peripheral blood progenitor or stem cells (PBPCs). The stimulatory effect of G-CSF and GM-CSF may be more pronounced when given after chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of recombinant G-CSF and GM-CSF in stem cell and progenitor cell mobilization will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/1\">",
"     1",
"    </a>",
"    ]. A more general discussion of hematopoietic stem cell mobilization is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link&amp;anchor=H9#H9\">",
"     \"Sources of hematopoietic stem cells\", section on 'Hematopoietic stem cell mobilization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STEM CELL AND PROGENITOR CELL MOBILIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF), either administered alone or in combination with chemotherapy, can be used to mobilize a mixture of stem and other cells from the bone marrow, referred to as peripheral blood progenitor or stem cells (PBPCs).",
"   </p>",
"   <p>",
"    Recombinant human G-CSF is the usual hematopoietic growth factor used to mobilize progenitors; the optimal dose of G-CSF is the subject of ongoing investigation, but ",
"1ff8",
"a higher dose (10",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day) may yield a greater content of CD34+ cells [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/2\">",
"     2",
"    </a>",
"    ]. Multiple apheresis procedures (ie, more than four) may be required to achieve this dose of CD34+ cells. As a result, a number of strategies have been designed to increase the yield and thereby reduce the number of apheresis procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link&amp;anchor=H11#H11\">",
"     \"Sources of hematopoietic stem cells\", section on 'Inadequate G-CSF response'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These include the use of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A combination of G-CSF with chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/3\">",
"       3",
"      </a>",
"      ] or GM-CSF (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link&amp;anchor=H14#H14\">",
"       \"Sources of hematopoietic stem cells\", section on 'Mobilization after chemotherapy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A combination of G-CSF with the CXCR4 inhibitor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/12/27844?source=see_link\">",
"       plerixafor",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link&amp;anchor=H13#H13\">",
"       \"Sources of hematopoietic stem cells\", section on 'Plerixafor (AMD3100, Mozobil)'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Stem cell factor (also called Steel factor) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/4-7\">",
"       4-7",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link&amp;anchor=H11#H11\">",
"       \"Sources of hematopoietic stem cells\", section on 'Inadequate G-CSF response'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A high affinity interleukin (IL)-3 receptor agonist [",
"      <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Flt3 ligand [",
"      <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/9-12\">",
"       9-12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Use of a longer-acting recombinant G-CSF (pegylated recombinant G-CSF,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/28/12741?source=see_link\">",
"     pegfilgrastim",
"    </a>",
"    , Neulasta&reg;), which requires less frequent dosing, has also resulted in successful mobilization [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link&amp;anchor=H523774212#H523774212\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\", section on 'Primary prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H200105123\">",
"    <span class=\"h2\">",
"     Granulocyte colony-stimulating factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     Granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) has an important effect on circulating hematopoietic progenitor cells (",
"    <a class=\"graphic graphic_algorithm graphicRef52024 \" href=\"UTD.htm?34/9/34968\">",
"     algorithm 1",
"    </a>",
"    ). After treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    and four days of recombinant human G-CSF, the absolute number of circulating progenitor cells of the granulocyte-macrophage, erythroid, mixed, and megakaryocyte lineages show a dose-related increase of up to 100-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/16\">",
"     16",
"    </a>",
"    ], confirming previous animal studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The relative proportion of the early and late granulocyte progenitors and of early progenitors of different lineages remains unchanged. However, CFU-E, which are normally undetectable in blood, are markedly increased.",
"   </p>",
"   <p>",
"    The mechanism by which G-CSF increases all progenitors in the blood is complex. G-CSF affects immature blast colony-forming cells, and it is possible that stem cells are stimulated in vivo to produce increased progenitors of all classes. In addition, G-CSF may indirectly stimulate progenitors by inducing the production of hematopoietic growth factor(s), and promotes the release of bone marrow progenitor cells and other cells such as lymphocytes into the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The integrin VLA-4, the chemokine receptor CXCR4, and c-kit, all expressed on progenitor cells, play critical roles in the adhesion of stem cells to stromal niches that express their corresponding ligands (VCAM-1, SDF-1, and Stem Cell Factor (SCF), respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/21\">",
"     21",
"    </a>",
"    ]. G-CSF stimulates stromal cells such as osteoblasts to secrete SDF-1. However, the increase in SDF-1 is transient because G-CSF also stimulates neutrophilic release of proteolytic enzymes such as neutrophil elastase and cathepsin G, which inactivate SDF-1 as well as part of the CXCR4 receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. In addition, SDF-1 induces osteoclasts to release a metalloproteinase MMP9, which cleaves and releases membrane-bound SCF [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H200105130\">",
"    <span class=\"h2\">",
"     Granulocyte-macrophage colony-stimulating factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulocyte-macrophage colony-stimulating factor (GM-CSF) also increases circulating progenitor cells of both erythroid and myeloid lineages, particularly when given after chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/3,28\">",
"     3,28",
"    </a>",
"    ]. In one study, for example, GM-CSF alone produced an 18-fold increase in blood CFU-GM and an eightfold increase in BFU-E; the effect on circulating progenitors was much greater (60-fold) when given during the recovery period after a course of cytotoxic chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These early studies set the stage for attempts at high dose chemotherapy followed by mobilized blood progenitor cell rescue in a number of chemosensitive tumors such as lymphoma and multiple myeloma. Time to engraftment is critically related to the number of CD34+ stem cells infused. A cell dose of 2 to 2.5 x 10",
"    <sup>",
"     6",
"    </sup>",
"    CD34+",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    produces rapid and sustained neutrophil and platelet engraftment in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/8,29\">",
"     8,29",
"    </a>",
"    ]. Some studies have suggested that a dose of more than 5 x 10",
"    <sup>",
"     6",
"    </sup>",
"    CD34+",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    produces more rapid platelet engraftment and assures rapid engraftment in patients who have had prolonged exposure to chemotherapy, although ",
"1ff8",
"the effects on myeloid engraftment have been minimal [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/4,8,30-33\">",
"     4,8,30-33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link&amp;anchor=H10#H10\">",
"     \"Sources of hematopoietic stem cells\", section on 'Optimal CD34 cell dose'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EX VIVO EXPANSION OF STEM AND PROGENITOR CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recognition that hematopoietic growth factors play a major role in the proliferation and differentiation of immature cells has led to intense interest in ex vivo expansion of stem and progenitor cells for clinical use [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/34\">",
"     34",
"    </a>",
"    ]. Since the rapidity, degree, and longevity of engraftment is dependent upon the number and quality of transplanted stem cells, the ability to expand these critical cells might have great clinical potential in graft engineering, tumor purging, and gene therapy. Current efforts to achieve the goal of ex vivo culture and amplification of hematopoietic stem cells have mainly involved the use of different cytokine combinations. However, there is little evidence to support the notion that the true long-term repopulating human stem cell (LTR-HSC) can be induced to divide and self-renew under such conditions, raising the concern that even if cell division is induced, the dividing cells may differentiate and eventually die.",
"   </p>",
"   <p>",
"    Several factors such as stem cell factor, flt3 ligand, IL-3, IL-6, IL-11, G-CSF, and GM-CSF appear to act on very primitive hematopoietic cells, including stem cells (",
"    <a class=\"graphic graphic_algorithm graphicRef52024 \" href=\"UTD.htm?34/9/34968\">",
"     algorithm 1",
"    </a>",
"    ). Despite intensive investigation, only murine studies have demonstrated that cytokines can increase self-renewal among the most immature HSCs capable of self-renewal and long-term hematopoietic reconstitution [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. In human studies, the lack of a suitable stem cell assay has made it difficult to investigate the regulatory mechanisms of HSC self-renewal. Very high concentrations of a combination of stem cell factor, flt3 ligand, and IL-3 can lead to significant expansion of primitive human hematopoietic cells called long term culture initiating cells (LTC-IC) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/37\">",
"     37",
"    </a>",
"    ]; however, the relationship of this cell to LTR-HSC is uncertain.",
"   </p>",
"   <p>",
"    Xenogeneic assays, in which human cells are injected into immunodeficient non-obese",
"    <span class=\"nowrap\">",
"     diabetic/severe",
"    </span>",
"    combined immunodeficient",
"    <span class=\"nowrap\">",
"     (NOD/SCID)",
"    </span>",
"    mice, suggest that the SCID repopulating cell (SRC) assay detects a cell more primitive than the LTC-IC [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. Other reports suggest that it may be possible to maintain or increase SRC numbers in serum-free cultures supplemented with a cytokine combination comprised of stem cell factor, flt3 ligand, IL-3, IL-6, and G-CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. However, incubation of cord blood CD34+ cells in a similar combination of cytokines (stem cell factor, flt3 ligand, and IL-3) results in rapid loss of SRC activity over three days [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar concerns about ex vivo expansion may apply to human clinical studies. When expanded progenitors were used in myeloablated patients with hematopoietic malignancies, short-term but not long-term engraftment was observed, with failure to achieve sustained neutrophil engraftment and no evidence of platelet reconstitution [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/45\">",
"     45",
"    </a>",
"    ]. These data emphasize the need both for new approaches to investigate and induce human stem cell self-renewal and for caution in the clinical use of these ex vivo expanded cells [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. New growth factors may offer some promise. The basal combination of SCF, thrombopoietin (TPO), insulin-like growth factor-2 (IGF-2), and fibroblast growth factor-1 (FGF) allows survival and a low level human reconstitution in the NOD-SCID model. After supplementation with angiopoietin-like protein 5 and IGF-binding protein 2 (IGFBP2), this six-factor combination in serum-free medium leads to marked expansion of HSC as judged by reconstitution of NOD- SCID mice [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another approach to stem cell expansion is the activation of a Notch receptor through an immobilized form of its ligand Delta1. This strategy was applied to cord blood (CB) CD34+ cells in a phase I study of 10 patients who received double cord blood transplantation (dCBT) with one unmanipulated CB unit along with a second unit that had undergone Notch-mediated ex vivo expansion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/49\">",
"     49",
"    </a>",
"    ]. When compared with patients receiving concurrent unmanipulated dCBT, the patients who received one manipulated and one unmanipulated graft showed an average 164-fold expansion of CD34+ cells and a significantly shorter time to an absolute neutrophil count (ANC)",
"    <span class=\"nowrap\">",
"     &gt;500/microL",
"    </span>",
"    (16 versus 26 days). Other methods under clinical exploration include growth on mesenchymal stem cells and use of prostaglandin E2, which can enhance human stem cell expansion in Zebrafish [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is initial information that the human Lin-CD34- cell population may contain cells capable of acquiring colony-forming, as well as long-term multilineage repopulating abilities ex vivo, coincident with their conversion to a CD34+ phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/50\">",
"     50",
"    </a>",
"    ]. This expansion required the presence of a murine bone marrow stromal cell line, fetal calf serum, TPO,",
"    <span class=\"nowrap\">",
"     flk2/flt3",
"    </span>",
"    ligand, stem cell factor, G-CSF, IL-3, and IL-6.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Expansion of post-progenitor cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the difficulties in ex vivo expansion of stem cells, there has been considerable interest in amplifying \"post-progenitor\" cells, that is, myeloid and platelet precursors, for therapeutic use. Although a number of different hematopoietic growth factor combinations can generate impressive amplification [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/51\">",
"     51",
"    </a>",
"    ], possible clinically effective use of these cells has been reported in only a few instances, all involving incubation of CD34+ cells with various combinations of growth factors [",
"    <a class=\"abstract\" href=\"./use-of-recombinant-hematopoietic-growth-factors-in-stem-cell-and-progenitor-cell-mobili",
"1ff8",
"zation/abstract/52-57\">",
"     52-57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Incubation with combinations of recombinant megakaryocyte growth and development factor (MGDF, a product no longer available, see below), G-CSF, and stem cell factor expand granulocyte-macrophage colony-forming units (CFU-GM) 6- to 32-fold (median 14-fold) after 10 days incubation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/52,57\">",
"       52,57",
"      </a>",
"      ]. This product was infused into 14 patients with multiple myeloma following treatment with high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      with or without total body irradiation. The duration of severe neutropenia (absolute neutrophil count",
"      <span class=\"nowrap\">",
"       &lt;500/microL)",
"      </span>",
"      was reduced to a median of 1.5 days compared with six days in similarly-treated historical controls. No significant adverse events were noted in any recipient, and all patients experienced sustained platelet and neutrophil engraftment.",
"     </li>",
"     <li>",
"      Incubation with recombinant human pegylated MGDF and IL-1 for eight days increases the concentration of megakaryocyte colony forming cells (CFC-Meg) and megakaryocytes approximately fivefold [",
"      <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/53\">",
"       53",
"      </a>",
"      ]. In a feasibility study, 10 cancer patients (8 with breast cancer and 2 with non-Hodgkin lymphoma) undergoing autologous PBPC transplant received CFC-Meg generated ex vivo (range: 1 to 21 x 10",
"      <sup>",
"       5",
"      </sup>",
"      CD61+",
"      <span class=\"nowrap\">",
"       cells/kg)",
"      </span>",
"      together with unmanipulated PBPCs [",
"      <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/54\">",
"       54",
"      </a>",
"      ]. Eight patients required a single allogeneic platelet transfusion, whereas platelet transfusion support was not needed in two of the four patients receiving the highest doses of cultured CFC-Meg. This result compares favorably with a retrospective control group of 14 patients, all of whom required platelet transfusion support.",
"     </li>",
"     <li>",
"      Incubation with G-CSF, stem cell factor, and pegylated MGDF for nine days expanded myeloid cells by up to 80-fold [",
"      <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/55\">",
"       55",
"      </a>",
"      ]. This product was infused into 24 breast cancer patients receiving high dose chemotherapy together with unmanipulated PBPCs. Study patients had significantly shorter times to neutrophil and platelet recovery, fewer red cell transfusions, and shorter periods of hospitalization than 48 historical controls treated with similar CD34+ doses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While these studies with pegylated MGDF are interesting, it should be noted that the development of antibodies in both patients and volunteers given PEG-MGDF led to termination of further clinical development of this TPO formulation, since transient decreases in platelet count were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/58-61\">",
"     58-61",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     GENE TRANSFER INTO STEM CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrovirus-mediated gene transfer into long-lived pluripotent hematopoietic stem cells (HSCs) could provide permanent correction of hematopoietic gene dysfunction in a variety of genetic diseases. However, the results of initial clinical gene therapy trials have been disappointing, due to the low efficiency of gene transfer into HSCs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    poor expression in the differentiated progeny of these cells [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/62-65\">",
"     62-65",
"    </a>",
"    ], as well as leukemogenesis in a human immunodeficiency trial due to insertional mutagenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. Despite these setbacks, encouraging long-term results have been reported for children with severe combined immunodeficiency (both adenosine deaminase deficient and X-linked) as well as Wiskott-Aldrich syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Major problems regarding human retrovirus-mediated gene transfer include poor HSC expression of amphotropic receptors for the retroviral envelope gene [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/70,71\">",
"     70,71",
"    </a>",
"    ] and the quiescent state of the majority of HSCs, which does not favor the integration of retroviral vectors for which cell division is thought to be required [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/72\">",
"     72",
"    </a>",
"    ]. Difficulties in assaying human HSCs have compounded these problems, as protocols for clinical trials based upon results from in vitro clonogenic assays of human progenitors, in particular the long-term culture initiating cell (LTC-IC) assay, have not correlated with clinical outcome.",
"   </p>",
"   <p>",
"    One approach to the amphotropic receptor problem has been the development of new vectors such as a Moloney murine leukemia virus-based retrovirus pseudotyped with the vesicular stomatitis virus G protein (VSV-G) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/73\">",
"     73",
"    </a>",
"    ]. VSV-G pseudotyped retroviruses, like conventional retroviruses, can stably integrate into the host genome, but have a much broader host range than conventional retroviruses and are more stable, thereby permitting concentration by ultracentrifugation to more than 10",
"    <sup>",
"     9",
"    </sup>",
"    infectious particles per mL [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. These vectors can efficiently infect mammalian and non-mammalian cells that are resistant to infection by conventional Moloney based retroviruses. To increase the safety of vectors, there is an effort to avoid retroviral enhancers by introducing self-inactivating retroviral or lentiviral vectors with internal promoter elements, which better resemble the normal physiology of retroviruses. Lentivirus vectors may require less cytokine stimulation for efficient gene transfer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The problem of stem cell quiescence is usually approached by using hematopoietic growth factors ex vivo to stimulate stem and progenitor cells into cycle, and this paradigm has driven much research in animal models and clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/76-79\">",
"     76-79",
"    </a>",
"    ]. The human studies are based upon the observation that stimulation with combinations of HGFs such as IL-3, IL-6, and stem cell factor can increase the efficiency of gene transfer into LTC-IC in clinically applicable supernatant infection procedures in the absence of stroma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Although stromal support increases the efficiency of gene transfer and may be necessary for optimal stem cell survival [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/81-83\">",
"     81-83",
"    </a>",
"    ], stromal based gene transfer methods are impractical.",
"   </p>",
"   <p>",
"    Interesting murine",
"1ff8",
" genetic studies have shown that osteoblasts stimulated through the parathyroid hormone axis or through blocking of a bone morphogenetic signal (BMP) release the Jagged-1 ligand that expands stem cells through the Notch pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. A better understanding of HSC-stromal molecular interactions is likely to lead to new methods for mobilizing, expanding, and increasing gene transfer into HSC.",
"   </p>",
"   <p>",
"    In summary, although strategies using combinations of HGFs have increased the efficiency of gene transfer into in vitro clonogenic progenitors, there is little evidence that cytokines increase the frequency of gene transfer into long-term repopulating stem cells, as measured in blood cells obtained from patients. Furthermore, stimulation with HGFs may irreversibly alter HSC properties [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/44\">",
"     44",
"    </a>",
"    ], and there is now strong evidence that sustained human stem cell self-renewal may not be possible [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/86-88\">",
"     86-88",
"    </a>",
"    ]. The potential of human stem cells to self-renew appears to be finite, determined by replicative history [",
"    <a class=\"abstract\" href=\"UTD.htm?10/45/10969/abstract/89,90\">",
"     89,90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H200105115\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mobilized peripheral blood progenitor cells (PBPCs) are commonly used as the stem cell source in both autologous and allogeneic hematopoietic cell transplantation. This approach requires harvesting of primitive stem cells from the peripheral circulation, usually identified as CD34+ cells. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF), either administered as single agents or in combination with chemotherapy, can be used to mobilize the mixture of stem and other cells referred to as PBPCs. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Stem cell and progenitor cell mobilization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recombinant human G-CSF is the usual hematopoietic growth factor used to mobilize progenitors. Chemotherapy or other agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/12/27844?source=see_link\">",
"       plerixafor",
"      </a>",
"      ) may be added to increase stem cell yield. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Stem cell and progenitor cell mobilization'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link&amp;anchor=H13#H13\">",
"       \"Sources of hematopoietic stem cells\", section on 'Plerixafor (AMD3100, Mozobil)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Attempts at ex vivo expansion of stem and progenitor cells have had limited success and this approach remains investigational. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Ex vivo expansion of stem and progenitor cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gene therapy with retrovirus-mediated gene transfer into long-lived pluripotent hematopoietic stem cells is also investigational. Initial clinical trials were disappointing, due to the low efficiency of gene transfer into stem cells, poor expression of the transferred gene in the differentiated progeny of these cells, as well as leukemogenesis due to insertional mutagenesis. Although it is too soon to know whether the safety concerns have been addressed, more recent clinical trials with modified vectors have shown encouraging results. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Gene transfer into stem cells'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/1\">",
"      Gertz MA. Current status of stem cell mobilization. Br J Haematol 2010; 150:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/2\">",
"      Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24:3187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/3\">",
"      Socinski MA, Cannistra SA, Elias A, et al. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988; 1:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/4\">",
"      Glaspy JA, Shpall EJ, LeMaistre CF, et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 1997; 90:2939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/5\">",
"      Moskowitz CH, Stiff P, Gordon MS, et al. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients--results of a phase I/II trial. Blood 1997; 89:3136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/6\">",
"      Weaver A, Ryder D, Crowther D, et al. Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor. Blood 1996; 88:3323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/7\">",
"      Begley CG, Basser R, Mansfield R, et al. Enhanced levels and enhanced clonogenic capacity of blood progenitor cells following administration of stem cell factor plus granulocyte colony-stimulating factor to humans. Blood 1997; 90:3378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/8\">",
"      Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/9\">",
"      Brasel K, McKenna HJ, Charrier K, et al. Flt3 ligand synergizes with granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor to mobilize hematopoietic progenitor cells into the peripheral blood of mice. Blood 1997; 90:3781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/10\">",
"      Papayannopoulou T, Nakamoto B, Andrews RG, et al. In vivo effects of Flt3/Flk2 ligand on mobilization of hematopoietic progenitors in primates and potent synergistic enhancement with granulocyte colony-stimulating factor. Blood 1997; 90:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./use-of-recombinant-hemat",
"1ff8",
"opoietic-growth-factors-in-stem-cell-and-progenitor-cell-mobilization/abstract/11\">",
"      Molineux G, McCrea C, Yan XQ, et al. Flt-3 ligand synergizes with granulocyte colony-stimulating factor to increase neutrophil numbers and to mobilize peripheral blood stem cells with long-term repopulating potential. Blood 1997; 89:3998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/12\">",
"      Sudo Y, Shimazaki C, Ashihara E, et al. Synergistic effect of FLT-3 ligand on the granulocyte colony-stimulating factor-induced mobilization of hematopoietic stem cells and progenitor cells into blood in mice. Blood 1997; 89:3186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/13\">",
"      Kroschinsky F, H&ouml;lig K, Poppe-Thiede K, et al. Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors. Haematologica 2005; 90:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/14\">",
"      Isidori A, Tani M, Bonifazi F, et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 2005; 90:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/15\">",
"      Simona B, Cristina R, Luca N, et al. A single dose of Pegfilgrastim versus daily Filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy. Transfus Apher Sci 2010; 43:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/16\">",
"      D&uuml;hrsen U, Villeval JL, Boyd J, et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72:2074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/17\">",
"      Tamura M, Hattori K, Nomura H, et al. Induction of neutrophilic granulocytosis in mice by administration of purified human native granulocyte colony-stimulating factor (G-CSF). Biochem Biophys Res Commun 1987; 142:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/18\">",
"      Shimamura M, Kobayashi Y, Yuo A, et al. Effect of human recombinant granulocyte colony-stimulating factor on hematopoietic injury in mice induced by 5-fluorouracil. Blood 1987; 69:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/19\">",
"      L&eacute;vesque JP, Takamatsu Y, Nilsson SK, et al. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 2001; 98:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/20\">",
"      K&ouml;rbling M, Huh YO, Durett A, et al. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 1995; 86:2842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/21\">",
"      Papayannopoulou T. Mechanisms of stem-/progenitor-cell mobilization: the anti-VLA-4 paradigm. Semin Hematol 2000; 37:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/22\">",
"      L&eacute;vesque JP, Hendy J, Winkler IG, et al. Granulocyte colony-stimulating factor induces the release in the bone marrow of proteases that cleave c-KIT receptor (CD117) from the surface of hematopoietic progenitor cells. Exp Hematol 2003; 31:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/23\">",
"      Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002; 3:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/24\">",
"      L&eacute;vesque JP, Hendy J, Takamatsu Y, et al. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003; 111:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/25\">",
"      El Ouriaghli F, Fujiwara H, Melenhorst JJ, et al. Neutrophil elastase enzymatically antagonizes the in vitro action of G-CSF: implications for the regulation of granulopoiesis. Blood 2003; 101:1752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/26\">",
"      Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002; 109:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/27\">",
"      Yu X, Huang Y, Collin-Osdoby P, Osdoby P. Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration. J Bone Miner Res 2003; 18:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/28\">",
"      Siena S, Bregni M, Brando B, et al. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989; 74:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/29\">",
"      Negrin RS, Kusnierz-Glaz CR, Still BJ, et al. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. Blood 1995; 85:3334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/30\">",
"      Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13:2547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/31\">",
"      Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86:3961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./use-of-recombinant-hematopoietic-growth-factors-in-stem-cell-and-progeni",
"1ff8",
"tor-cell-mobilization/abstract/32\">",
"      Pecora AL, Preti RA, Gleim GW, et al. CD34+CD33- cells influence days to engraftment and transfusion requirements in autologous blood stem-cell recipients. J Clin Oncol 1998; 16:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/33\">",
"      Shpall EJ. The utilization of cytokines in stem cell mobilization strategies. Bone Marrow Transplant 1999; 23 Suppl 2:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/34\">",
"      Dahlberg A, Delaney C, Bernstein ID. Ex vivo expansion of human hematopoietic stem and progenitor cells. Blood 2011; 117:6083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/35\">",
"      Bodine DM, Seidel NE, Orlic D. Bone marrow collected 14 days after in vivo administration of granulocyte colony-stimulating factor and stem cell factor to mice has 10-fold more repopulating ability than untreated bone marrow. Blood 1996; 88:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/36\">",
"      Miller CL, Eaves CJ. Expansion in vitro of adult murine hematopoietic stem cells with transplantable lympho-myeloid reconstituting ability. Proc Natl Acad Sci U S A 1997; 94:13648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/37\">",
"      Zandstra PW, Conneally E, Petzer AL, et al. Cytokine manipulation of primitive human hematopoietic cell self-renewal. Proc Natl Acad Sci U S A 1997; 94:4698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/38\">",
"      Kamel-Reid S, Dick JE. Engraftment of immune-deficient mice with human hematopoietic stem cells. Science 1988; 242:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/39\">",
"      Vormoor J, Lapidot T, Pflumio F, et al. Immature human cord blood progenitors engraft and proliferate to high levels in severe combined immunodeficient mice. Blood 1994; 83:2489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/40\">",
"      Gan OI, Murdoch B, Larochelle A, Dick JE. Differential maintenance of primitive human SCID-repopulating cells, clonogenic progenitors, and long-term culture-initiating cells after incubation on human bone marrow stromal cells. Blood 1997; 90:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/41\">",
"      Larochelle A, Vormoor J, Hanenberg H, et al. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. Nat Med 1996; 2:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/42\">",
"      Conneally E, Cashman J, Petzer A, Eaves C. Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic-scid/scid mice. Proc Natl Acad Sci U S A 1997; 94:9836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/43\">",
"      Bhatia M, Bonnet D, Kapp U, et al. Quantitative analysis reveals expansion of human hematopoietic repopulating cells after short-term ex vivo culture. J Exp Med 1997; 186:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/44\">",
"      Rebel VI, Tanaka M, Lee JS, et al. One-day ex vivo culture allows effective gene transfer into human nonobese diabetic/severe combined immune-deficient repopulating cells using high-titer vesicular stomatitis virus G protein pseudotyped retrovirus. Blood 1999; 93:2217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/45\">",
"      Holyoake TL, Alcorn MJ, Richmond L, et al. CD34 positive PBPC expanded ex vivo may not provide durable engraftment following myeloablative chemoradiotherapy regimens. Bone Marrow Transplant 1997; 19:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/46\">",
"      Scheding S, Kratz-Albers K, Meister B, et al. Ex vivo expansion of hematopoietic progenitor cells for clinical use. Semin Hematol 1998; 35:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/47\">",
"      Ram&iacute;rez M, Segovia JC, Benet I, et al. Ex vivo expansion of umbilical cord blood (UCB) CD34(+) cells alters the expression and function of alpha 4 beta 1 and alpha 5 beta 1 integrins. Br J Haematol 2001; 115:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/48\">",
"      Zhang CC, Kaba M, Iizuka S, et al. Angiopoietin-like 5 and IGFBP2 stimulate ex vivo expansion of human cord blood hematopoietic stem cells as assayed by NOD/SCID transplantation. Blood 2008; 111:3415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/49\">",
"      Delaney C, Heimfeld S, Brashem-Stein C, et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010; 16:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/50\">",
"      Nakamura Y, Ando K, Chargui J, et al. Ex vivo generation of CD34(+) cells from CD34(-) hematopoietic cells. Blood 1999; 94:4053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/51\">",
"      Hino M, Suzuki K, Yamane T, et al. Ex vivo expansion of mature human neutrophils with normal functions from purified peripheral blood CD34+ haematopoietic progenitor cells. Br J Haematol 2000; 109:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/52\">",
"      Reiffers J, Cailliot C, Dazey B, et al. Abrogation of post-myeloablative chemotherapy neutropenia by ex-vivo expanded autologous CD34-positive cells. Lancet 1999; 354:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/53\">",
"      van den Oudenrijn S, de Haas M, Calafat J, et al. A combination of megakaryocyte growth and development factor and interleukin-1 is sufficient to culture large numbers of megakaryocytic progenitors and megakaryocytes for transfusion purposes. Br J Haematol 1999; 106:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/54\">",
"      Bertolini F, Battaglia M, Pedrazzoli P, et al. Megakaryocytic progenitors can be generated ex vivo and safely administered to autologous peripheral blood progenitor cell transplant recipients. Blood 1997; 89:2679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"/conten",
"1ff8",
"ts/use-of-recombinant-hematopoietic-growth-factors-in-stem-cell-and-progenitor-cell-mobilization/abstract/55\">",
"      Paquette RL, Dergham ST, Karpf E, et al. Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer. Blood 2000; 96:2385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/56\">",
"      Prince HM, Simmons PJ, Whitty G, et al. Improved haematopoietic recovery following transplantation with ex vivo-expanded mobilized blood cells. Br J Haematol 2004; 126:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/57\">",
"      Boiron JM, Dazey B, Cailliot C, et al. Large-scale expansion and transplantation of CD34(+) hematopoietic cells: in vitro and in vivo confirmation of neutropenia abrogation related to the expansion process without impairment of the long-term engraftment capacity. Transfusion 2006; 46:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/58\">",
"      Crawford J, Glaspy J, Belani C, et al. A randomized, placebo-controlled, blinded, dose-scheduling trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) with filgastrim support in small non-lung cancer (NSCLC) patients treated with paclitaxel and carboplatin during multiple cycles of chemotherapy. Proc Am Soc Clin Oncol 1998; 17:73a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/59\">",
"      Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98:3241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/60\">",
"      Harker LA. Physiology and clinical applications of platelet growth factors. Curr Opin Hematol 1999; 6:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/61\">",
"      Yang C, Xia Y, Li J, Kuter DJ. The appearance of anti-thrombopoietin antibody and circulating thrombopoietin-IgG complexes in a patient developing thrombocytopenia after the injection of PEG-rHuMGDF. Blood 1999; 94:681a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/62\">",
"      Dunbar CE, Cottler-Fox M, O'Shaughnessy JA, et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995; 85:3048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/63\">",
"      Bordignon C, Notarangelo LD, Nobili N, et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science 1995; 270:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/64\">",
"      Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science 1995; 270:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/65\">",
"      Kohn DB, Weinberg KI, Nolta JA, et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med 1995; 1:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/66\">",
"      Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/67\">",
"      Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/68\">",
"      Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/69\">",
"      Booth C, Gaspar HB, Thrasher AJ. Gene therapy for primary immunodeficiency. Curr Opin Pediatr 2011; 23:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/70\">",
"      Kavanaugh MP, Miller DG, Zhang W, et al. Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters. Proc Natl Acad Sci U S A 1994; 91:7071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/71\">",
"      Orlic D, Girard LJ, Jordan CT, et al. The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction. Proc Natl Acad Sci U S A 1996; 93:11097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/72\">",
"      Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990; 10:4239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/73\">",
"      Emi N, Friedmann T, Yee JK. Pseudotype formation of murine leukemia virus with the G protein of vesicular stomatitis virus. J Virol 1991; 65:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/74\">",
"      Friedmann T, Yee JK. Pseudotyped retroviral vectors for studies of human gene therapy. Nat Med 1995; 1:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/75\">",
"      Burns JC, Friedmann T, Driever W, et al. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci U S A 1993; 90:8033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/76\">",
"      Bodine DM, Karlsson S, Nienhuis AW. Combination of interleukins 3 and 6 preserves stem cell function in culture and enhances retrovirus-mediated gene transfer into hematopoietic stem cells. Proc Natl Acad Sci U S A 1989; 86:8897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/77\">",
"      Laneuville P, Chang W, Kamel-Reid S, et al. High-efficiency gene transfer and expression in normal human hematopoietic cells with retrovirus vectors. Blood ",
"1ff8",
"1988; 71:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/78\">",
"      Dick JE, Kamel-Reid S, Murdoch B, Doedens M. Gene transfer into normal human hematopoietic cells using in vitro and in vivo assays. Blood 1991; 78:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/79\">",
"      Hughes PF, Eaves CJ, Hogge DE, Humphries RK. High-efficiency gene transfer to human hematopoietic cells maintained in long-term marrow culture. Blood 1989; 74:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/80\">",
"      Hughes PF, Thacker JD, Hogge D, et al. Retroviral gene transfer to primitive normal and leukemic hematopoietic cells using clinically applicable procedures. J Clin Invest 1992; 89:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/81\">",
"      Xu LC, Kluepfel-Stahl S, Blanco M, et al. Growth factors and stromal support generate very efficient retroviral transduction of peripheral blood CD34+ cells from Gaucher patients. Blood 1995; 86:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/82\">",
"      Moore KA, Deisseroth AB, Reading CL, et al. Stromal support enhances cell-free retroviral vector transduction of human bone marrow long-term culture-initiating cells. Blood 1992; 79:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/83\">",
"      Nolta JA, Smogorzewska EM, Kohn DB. Analysis of optimal conditions for retroviral-mediated transduction of primitive human hematopoietic cells. Blood 1995; 86:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/84\">",
"      Zhang J, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003; 425:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/85\">",
"      Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003; 425:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/86\">",
"      Harrison DE, Stone M, Astle CM. Effects of transplantation on the primitive immunohematopoietic stem cell. J Exp Med 1990; 172:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/87\">",
"      Spangrude GJ, Brooks DM, Tumas DB. Long-term repopulation of irradiated mice with limiting numbers of purified hematopoietic stem cells: in vivo expansion of stem cell phenotype but not function. Blood 1995; 85:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/88\">",
"      Van Zant G, de Haan G, Rich IN. Alternatives to stem cell renewal from a developmental viewpoint. Exp Hematol 1997; 25:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/89\">",
"      Morrison SJ, Wandycz AM, Akashi K, et al. The aging of hematopoietic stem cells. Nat Med 1996; 2:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/45/10969/abstract/90\">",
"      Van Zant G, Holland BP, Eldridge PW, Chen JJ. Genotype-restricted growth and aging patterns in hematopoietic stem cell populations of allophenic mice. J Exp Med 1990; 171:1547.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3556 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.28.111.102-322217C268-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_45_10969=[""].join("\n");
var outline_f10_45_10969=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H200105115\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STEM CELL AND PROGENITOR CELL MOBILIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H200105123\">",
"      Granulocyte colony-stimulating factor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H200105130\">",
"      Granulocyte-macrophage colony-stimulating factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EX VIVO EXPANSION OF STEM AND PROGENITOR CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Expansion of post-progenitor cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GENE TRANSFER INTO STEM CELLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H200105115\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/3556\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3556|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?34/9/34968\" title=\"algorithm 1\">",
"      Hematopoiesis regulation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=related_link\">",
"      Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_45_10970="Anterior neck muscles A";
var content_f10_45_10970=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76977%7EPEDS%2F56033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76977%7EPEDS%2F56033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Anterior neck muscles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 413px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The anterior neck muscles include the platysma, sternocleidomastoid (SCM), anterior vertebral muscles, and the lateral vertebral muscles. The platysma is a broad, thin muscle that overlies the other muscles and neck structures. The SCM arises from the sternum and the medial third of the clavicle and passes obliquely across the side of the neck to insert into the mastoid process. The anterior vertebral muscles include the longus capitis, longus colli, rectus capitis anterior, and rectus capitis lateralis (only the longus capitus is visible on this view). The lateral vertebral muscles (scalene muscles), attach from the cervical vertebrae to the first or second ribs. The nerves of the brachial plexus pass between the anterior and middle scalene muscles en route to the subclavian area.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    The prevertebral region and root of the neck, anterior view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 559px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_45_10970=[""].join("\n");
var outline_f10_45_10970=null;
var title_f10_45_10971="Paraphimosis reduction tips";
var content_f10_45_10971=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Paraphimosis reduction: procedure tips",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Patients with hair tourniquet or other constricting bands have physical findings that are very similar to paraphimosis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Patients with glans penis ischemia with necrosis require emergent urologic consultation and preparation for invasive reduction utilizing procedural sedation in the ED or general anesthesia in the OR.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Adequate pain control is essential for the cooperation necessary to achieve a successful reduction at the bedside.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Most young boys are best served with procedural sedation for paraphimosis reduction.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Adjuncts require a significant amount of time to have an important impact on foreskin and glans penis swelling and should not be used when penile necrosis is evident.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. The compression time during a successful manual reduction of a paraphimosis often exceeds 5 minutes.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_45_10971=[""].join("\n");
var outline_f10_45_10971=null;
var title_f10_45_10972="Common etiologies of cardiac arrest in adults";
var content_f10_45_10972=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common etiologies of cardiac arrest in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiac",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute coronary syndrome (most common)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arrhythmia: Secondary to electrolyte disorder, acidosis, other process; abnormal conduction syndromes (eg, prolonged QT, Brugada)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pericardial tamponade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Respiratory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Airway obstruction: Mucus plug, foreign body, tracheostomy decannulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asthma/COPD exacerbation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary embolus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tension pneumothorax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hemmorhage and hypovolemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal aortic aneursym rupture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intracranial hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Profound gastrointestinal fluid loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drugs and poisons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Opioids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beta blockers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium-channel blockers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benzodiazepines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tricyclic antidepressants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Digoxin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Electrolyte disturbances",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Potassium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Magnesium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Sepsis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_45_10972=[""].join("\n");
var outline_f10_45_10972=null;
var title_f10_45_10973="CEAP classification for chronic venous disorders";
var content_f10_45_10973=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F52388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F52388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    CEAP classification for chronic venous disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Clinical classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C",
"        <sub>",
"         0",
"        </sub>",
"       </td>",
"       <td>",
"        No visible or palpable signs of venous disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C",
"        <sub>",
"         1",
"        </sub>",
"       </td>",
"       <td>",
"        Telangiectasias, reticular veins, malleolar flares",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"       <td>",
"        Varicose veins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C",
"        <sub>",
"         3",
"        </sub>",
"       </td>",
"       <td>",
"        Edema without skin changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        C",
"        <sub>",
"         4",
"        </sub>",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        Skin changes ascribed to venous disease (eg, pigmentation, venous eczema, lipodermatosclerosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        C",
"        <sub>",
"         4a",
"        </sub>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Pigmentation or eczema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        C",
"        <sub>",
"         4b",
"        </sub>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Lipodermatosclerosis or atrophie blanche",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C",
"        <sub>",
"         5",
"        </sub>",
"       </td>",
"       <td>",
"        Skin changes as defined above with healed ulceration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C",
"        <sub>",
"         6",
"        </sub>",
"       </td>",
"       <td>",
"        Skin changes as defined above with active ulceration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        Symptomatic, including ache, pain, tightness, skin irritation, heaviness, and muscle cramps, and other complaints attributable to venous dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A",
"       </td>",
"       <td>",
"        Asymptomatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Etiologic classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ec",
"       </td>",
"       <td>",
"        Congenital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ep",
"       </td>",
"       <td>",
"        Primary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Es",
"       </td>",
"       <td>",
"        Secondary (postthrombotic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        En",
"       </td>",
"       <td>",
"        No venous cause identified",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Anatomic classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        As",
"       </td>",
"       <td>",
"        Superficial veins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ap",
"       </td>",
"       <td>",
"        Perforator veins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ad",
"       </td>",
"       <td>",
"        Deep veins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        An",
"       </td>",
"       <td>",
"        No venous location identified",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Pathophysiologic classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pr",
"       </td>",
"       <td>",
"        Reflux",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Po",
"       </td>",
"       <td>",
"        Obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pr,o",
"       </td>",
"       <td>",
"        Reflux and obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pn",
"       </td>",
"       <td>",
"        No venous pathophysiology identifiable",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Limbs in higher categories have more severe signs of chronic venous disease and may have some or all of the findings defining a less severe clinical category. Each limb is further characterized as asymptomatic (A), for example, C0-6,A, or symptomatic (S), for example, C0-6,S. Symptoms that may be associated with telangiectatic, reticular, or varicose veins include lower extremity aching, pain, and skin irritation. Therapy may alter the clinical category of chronic venous disease. Limbs should therefore be reclassified after any form of medical or surgical treatment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Eklof B, Rutherford R, Bergan J, et al. Revision of the CEAP classification for chronic venous disorders: Consensus statement. J Vasc Surg 2004; 40:1248.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_45_10973=[""].join("\n");
var outline_f10_45_10973=null;
var title_f10_45_10974="Autosomal dominant pedigree";
var content_f10_45_10974=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 577px\">",
"   <div class=\"ttl\">",
"    Pedigree of autosomal dominant inheritance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 557px; height: 289px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple generations are affected.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Linda Pinsky, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_45_10974=[""].join("\n");
var outline_f10_45_10974=null;
var title_f10_45_10975="Murless head elevator";
var content_f10_45_10975=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Murless head elevator",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 426px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_45_10975=[""].join("\n");
var outline_f10_45_10975=null;
